Bispecific antibodies that bind to NKP46 and MICA / b

Improved bispecific antibodies with optimized MICA/B and NKp46 antigen binding domains enhance NK cell activation and tumor cell killing, addressing the limitations of current antibodies in cancer therapy.

WO2025085672A1PCT designated stage expired Publication Date: 2025-04-24XENCOR INC +9
View PDF 86 Cites 2 Cited by

Patent Information

Application Number
PCT/US2024/051832
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-15
Filing Date
2024-10-17
Publication Date
2025-04-24

AI Technical Summary

Technical Problem

Current bispecific antibodies that target NKP46 and MICA/B antigens are not optimized for effective cancer therapy, as they lack specific antigen binding domains that enhance NK cell activation and tumor cell killing.

Method used

Development of improved bispecific antibodies with specific MICA/B and NKp46 antigen binding domains, comprising selected variable heavy and light domain pairs, to enhance NK cell engagement and activation against cancer cells.

Benefits of technology

The improved bispecific antibodies demonstrate enhanced binding affinity and specificity to NKP46 and MICA/B antigens, leading to increased NK cell activation and improved cytotoxic killing of tumor cells, potentially offering a more effective cancer therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000122_0001
    Figure IMGF000122_0001
  • Figure IMGF000123_0001
    Figure IMGF000123_0001
  • Figure 00000427_0000
    Figure 00000427_0000
Patent Text Reader

Abstract

Provided herein are anti-NKp46 × anti-MICA / B antibodies and methods of using such antibodies for the treatment of MICA / B-associated cancers, as well as anti-NKp46 × anti-B7H3 antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

BISPECIFIC ANTIBODIES THAT BIND TO NKP46 AND MICA / BCROSS-REFERENCE

[0001] This application claims priority to U.S. Provisional Application No. 63 / 590,925, filed on October 17, 2023, U.S. Provisional Application No. 63 / 594,672, filed on October 31, 2023, and U.S. Provisional Application No. 63 / 610,815, filed on December 15, 2023, which are incorporated herein by reference in their entirety.BACKGROUND

[0002] Antibody-based therapeutics have been used successfully to treat a variety of diseases, including cancer. An increasingly prevalent avenue being explored is the engineering of single immunoglobulin molecules that co-engage two different antigens. Such alternate antibody formats that engage two different antigens are often referred to as bispecific antibodies. Because the considerable diversity of the antibody variable region (Fv) makes it possible to produce an Fv that recognizes virtually any molecule, the typical approach to bispecific antibody generation is the introduction of new variable regions into the antibody.

[0003] Natural killer cell engagers (NKEs), a new class of immune-oncology therapeutics, contain fragments of antibodies such as antibody binding domains and are designed to exploit the immune functions of NK cells in cancer.

[0004] NK cells are part of the innate immune system and represent 5-20% of circulating lymphocytes in humans. NK cells infiltrate virtually all tissues and were originally characterized by their ability to kill tumor cells effectively without the need for prior sensitization. This ability to infiltrate also occurs in the tumor microenvironment and this infiltration is associated with better overall survival in patients.

[0005] Activated NK cells kill target cells by means similar to cytotoxic T cells, using cytolytic granules as well as through death receptor pathways. When NK cells encounter foreign or cancer cells, they are activated via there activating receptors, including NKp46. Thus, similar to “T Cell Engagers” (TCEs), that bind to CD3 on T Cells and a tumor antigen on a tumor cell to drive cytotoxic killing of the tumor cell, Natural Killer Engagers (NKEs) can be made that bind to theNK cells and a tumor cell and similarly facilitate cytotoxic killing.

[0006] Natural killer group 2 member D (NKG2D) is an activating receptor present on the surface of natural killer (NK) cells, some NK T cells, CD8+ cytotoxic T cells, y5 T cells, and CD4+ T cells, under certain conditions. (Champsaur M, Lanier L L. Immunol Rev 2010; 235:267-85; Jamieson A M, Diefenbach A, McMahon C W, et al. Immunity 2002; 17:19-29). MICA and MICB (MICA / B) are NKG2D ligands which can, in some instances, be upregulated in several human cancers. Further MICA / B are transmembrane proteins with MHC-like extracellular domains that do not associate with beta-2 microglobulin nor present antigens. The proteins can undergo proteolytic cleavage in a multistep process and thereafter, the solubleMICA / B can bind NKG2D on NK cells. In some cases, the soluble MICA / B is shed in the blood plasma and serum in subjects with cancer.

[0007] The present disclosure is directed to improved bispecific MICA / B and NKp46 antibodies and the use of such antibodies for use in therapy (e.g., cancer therapy).SUMMARY

[0008] In one aspect, the present disclosure provides a MICA / B antigen binding domain comprising a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B ]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX- XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ IDNOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICAZB]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICAZB]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICAZB]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B] H2 DI 03388 1D7 [MICA / B] LI, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H0_D105317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JA2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 J A2 [MICA / B]_H2_D105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D 105317 1 C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7[MICAZB]_LO, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICAZB]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B] HO D94837 1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1 -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, and (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, as depicted in Figure 21.

[0009] In another aspect, the present disclosure provides a MICA / B antigen binding domain comprising a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_HO_D94837_1E1 1 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_IE11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5[MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852 2E12 [MICA / B] H2 D94852 2E12 [MICA / B] LI, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D103388 J C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L 1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for DI 05317 1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317 1 A2 [MICA / B ]_H1_D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B] HO D103388 1B11-2 [MICA / B] LO, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D1O5317_1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317_lF6 [MICA / B ]_H0_D 105317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, and (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, as depicted in Figure 21.

[0010] In another aspect, the present disclosure provides an antibody comprising a MICA / B antigen binding domain (as described above).

[0011] In a further embodiment and in accordance with the above, the antibody is a monoclonal antibody or a bispecific antibody.

[0012] In another aspect, the present disclosure provides a composition comprising a MICA / B antigen binding domain or an antibody (as described above).

[0013] In another aspect, the present disclosure provides a nucleic acid composition comprising: (a) a first nucleic acid encoding a variable heavy domain (as described above), and (b) a secondnucleic acid encoding a variable light domain (as described above).

[0014] In another aspect, the present disclosure provides an expression vector composition comprising: (a) a first expression vector comprising a first nucleic acid (as described above), and (b) a second expression vector comprising a second nucleic acid (as described above).

[0015] In another aspect, the present disclosure provides a host cell comprising an expression vector composition (as described above).

[0016] In another aspect, the present disclosure provides a method of making a MICA / B antigen binding domain or an antibody comprising such, the method comprising: (a) culturing a host cell (as described above) under conditions wherein the MICA / B antigen binding domain or the antibody comprising such is expressed, and (b) recovering the MICA / B antigen binding domain or the antibody comprising such.

[0017] In another aspect, the present disclosure provides a NKp46 antigen binding domain comprising a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, as depicted in Figure 23.

[0018] In another aspect, the present disclosure provides a NKp46 antigen binding domain comprising a variable heavy domain and variable light domain pair selected from the group including: SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, as depicted in Figure 23.

[0019] In another aspect, the present disclosure provides an antibody comprising a NKp46 antigen binding domain (as described above).

[0020] In a further embodiment and in accordance with the above, the antibody is a monoclonal antibody or a bispecific antibody.

[0021] In another aspect, the present disclosure provides a composition comprising a NKp46 antigen binding domain or an antibody (as described above).

[0022] In another aspect, the present disclosure provides a nucleic acid composition comprising: (a) a first nucleic acid encoding a variable heavy domain (as described above), and (b) a secondnucleic acid encoding a variable light domain (as described above).

[0023] In another aspect, the present disclosure provides an expression vector composition comprising: (a) a first expression vector comprising a first nucleic acid (as described above), and (b) a second expression vector comprising a second nucleic acid (as described above).

[0024] In another aspect, the present disclosure provides a host cell comprising an expression vector composition (as described above).

[0025] In another aspect, the present disclosure provides a method of making a NKp46 antigen binding domain or an antibody comprising such, the method comprising: (a) culturing a host cell (as described above) under conditions wherein the NKp46 antigen binding domain or the antibody comprising such is expressed, and (b) recovering the NKp46 antigen binding domain or the antibody comprising such.

[0026] In another aspect, the present disclosure provides a heterodimeric antibody, comprising:(a) a first monomer, comprising: (i) an anti-NKp46 scFv comprising a first variable heavy VH1 domain, an scFv linker, and a first variable light VL1 domain; and (ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;(b) a second monomer comprising a VH2-CHl-hinge-CH2-CH3 monomer, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain; and (c) a light chain comprising a second variable light VL2 domain, wherein the second variable heavy VH2 domain and the second variable light VL2 domain form a MICA / B antigen binding domain.

[0027] In a further embodiment and in accordance with the above, the MICA / B antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a vailable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11_1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICAZB]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B] Hl 2E5 [MICA / B] LI, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICAZB]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B] HO DI 03388 1D7 [MICA / B] LO, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 J A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6[MICAZB]_LO, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F6 [MICA / B]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B] HO D105317 1F7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 7C6 [MICA / B ]_H0_7C 6 [MICA / B ]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depictedin Figures 21 and 22.

[0028] In a further embodiment and in accordance with any of the above, the MICA / B antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11_1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837JE11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5[MICA / B] H2 2E5 [MICA / B] L2, (xi) SEQ ID Nos: XXX and XXX for D94852 2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [M1CA / B]_LO, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_HO_D1O3388_1D7[MICA / B]_LO, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] H2 D103388 1D7 [MICA / B] L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H I D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317 1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317JF7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [M1CA / B]_HO_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXXand XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B] HO 6E1[MICA / B] _L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICAZB]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0029] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and first variable light VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46] H NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0030] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0031] In a further embodiment and in accordance with any of the above, the first variable light VL1 domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the first variable heavy VH1 domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0032] In a further embodiment and in accordance with any of the above, the heterodimeric antibody comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence, wherein the first, second, and third amino acid sequences are selected from the group including: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP46810, (ii) the amino acid sequences of SEQ ID NOS: XXX-XXX of XENP46811, and (iii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP46812, as depicted in Figure 31.

[0033] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0034] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0035] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0036] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0037] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0038] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0039] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0040] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0041] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W: T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0042] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0043] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0044] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0045] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0046] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0047] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0048] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0049] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0050] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0051] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0052] In another aspect, the present disclosure provides a heterodimeric antibody, comprising:(a) a first monomer, comprising: (i) an anti-MICA / B scFv comprising a first variable heavy VH1 domain, an scFv linker, and a first variable light VL1 domain; and (ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;(b) a second monomer comprising a VH2-CHl-hinge-CH2-CH3 monomer, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain; and (c) a light chain comprising a second variable light VL2 domain, wherein the second variable heavy VH2 domain and the second variable light VL2 domain form a NKp46 antigen binding domain.

[0053] In a further embodiment and in accordance with the above, the NKp46 antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_ NKp46- A[NKp46] L, as depicted in Figures 23 and 24.

[0054] In a further embodiment and in accordance with any of the above, the NKp46 antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0055] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl -3 from a first variable heavy VH1 domain and first variable light VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1[MICA / B] HO D94837 1E11 1 [MICA / B] L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICAZB]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B] Hl 2E5 [MICA / B] LI, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICAZB]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B] HO DI 03388 1D7 [MICA / B] L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H0_D105317_lA2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 J A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6[MICAZB]_LO, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F6 [MICA / B]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B] HO D105317 1F7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 7C6 [MICA / B ]_H0_7C 6 [MICA / B ]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depictedin Figures 21 and 22.

[0056] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837JE11 1 [MICA / B]_HO_D94837_1E11_1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX forD94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5[MICA / B] H2 2E5 [MICA / B] L2, (xi) SEQ ID Nos: XXX and XXX for D94852 2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [M1CA / B]_LO, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_HO_D1O3388_1D7[MICA / B]_LO, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] H2 D103388 1D7 [MICA / B] L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H I D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317 1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317JF7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [M1CA / B]_HO_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXXand XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B] HO 6E1[MICA / B] _L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0057] In a further embodiment and in accordance with any of the above, the first variable light VL1 domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the first variable heavy VH1 domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0058] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0059] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0060] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0061] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0062] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298 A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0063] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D :WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0064] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0065] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0066] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0067] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0068] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0069] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0070] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0071] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0072] In a further embodiment and in accordance with any of the above, the first and secondmonomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0073] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0074] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0075] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0076] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0077] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0078] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -[first optional domain linker]-scFv-[second optional domain linker]-CH2-CH3, wherein VH1 is a first variable heavy VH1 domain, scFv is an anti-MICA / B scFv, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N-terminus to C-terminus, a CH2-CH3, wherein the CH2- CH3 is a second Fc domain; and (c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light VH1 domain and CL is a constant light domain, wherein: (i) the first variable heavy VH1 domain and the first variable light VL1 domain form a NKp46 antigen binding domain, (ii) the anti-MICA / B scFv comprises a second variable heavy VH2 domain, a scFv linker, and a second variable light VL2 domain, and (iii) the anti-MICA / B scFv is covalently attached between the C-terminus of the CHI domain and the N-terminus of the first Fc domain.

[0079] In a further embodiment and in accordance with the above, the NKp46 antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0080] In a further embodiment and in accordance with any of the above, the NKp46 antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0081] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11_1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1E11 1 [MICA / B] Hl D94837 1E11 1 [MICA / B] LI, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837_1E11_1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX- XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICAZB]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICAZB]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B] H2 D94852 2E12 [MICA / B] LI, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICAZB]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICAZB]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388JC7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7[MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1A2 [MICA / B] Hl D105317 1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICAZBJ LO, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXXforvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B] L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6 [MICA / B ]_H0_7C 6 [MICA / B ]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0082] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX andXXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICAZB]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852 2E12 [MICA / B] Hl D94852 2E12 [MICA / B] LI, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L 1, (xxv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX andXXX for D99136_2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B] LI, (xl) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317 1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837JD9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0083] In a further embodiment and in accordance with any of the above, wherein: (i) the anti- MICA / B scFv comprises, from N-terminus to C-terminus, VH2-scFv linker- VL2, (ii) the variable heavy domain is covalently attached to the C-terminus of the CHI domain, optionallyusing a first domain linker, and (iii) the variable light domain is covalently attached to the N- terminus of the first Fc domain, optionally using a second domain linker; or (i) the anti -MIC A / B scFv comprises, from N-terminus to C-terminus, VL2-scFv linker- VH2, (ii) the variable light domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker, and (iii) the variable heavy domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker.

[0084] In a further embodiment and in accordance with any of the above, the heterodimeric antibody comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence, wherein the first, second, and third amino acid sequences are selected from the group including: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47274, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47281, as depicted in Figure 32.

[0085] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0086] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0087] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0088] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0089] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298 A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0090] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D :WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0091] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0092] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0093] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0094] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0095] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0096] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0097] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0098] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0099] In a further embodiment and in accordance with any of the above, the first and secondmonomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0100] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0101] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0102] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0103] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0104] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0105] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -[first optional domain linker]-scFv-[second optional domain linker]-CH2-CH3, wherein VH1 is a first variable heavy VH1 domain, scFv is an anti-NKp46 scFv, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N-terminus to C-terminus, a CH2-CH3, wherein the CH2- CH3 is a second Fc domain; and (c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light VH1 domain and CL is a constant light domain, wherein: (i) the first variable heavy VH1 domain and the first variable light VL1 domain form a MICA / B antigen binding domain, (ii) the anti-NKp46 scFv comprises a second variable heavy VH2 domain, a scFv linker, and a second variable light VL2 domain, and (iii) the anti-NKp46 scFv is covalently attached between the C-terminus of the CHI domain and the N-terminus of the first Fc domain.

[0106] In a further embodiment and in accordance with the above, the MICA / B antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICAZB]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICAZB]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B] _L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD103388JD7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136 2C11 [MICA / B] H2 D99136 2C 11 [MICA / B] L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_HO_D1O5317 1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F6 [MICA / B]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8[MICAZB]_H0_D88487_2A8 [MICA / B]_LO, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0107] In a further embodiment and in accordance with any of the above, the MICA / B antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11_1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] Hl D94837 1E11 1 [MICA / B] LI, (iii) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7[MICAZB]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICAZB]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B] Hl D103388 1C7 [MICA / B] _L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for DI 05317 1 A2 [MICA / B]_H0_D105317_l A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D105317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317 1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0,(xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B]_HO_D94837_1D8 [MICAZB]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852 2D4 [MICA / B] HO D94852 2D4 [MICA / B] LO, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837 3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0108] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0109] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0110] In a further embodiment and in accordance with any of the above, wherein: (i) the anti- NKp46 scFv comprises, from N-terminus to C-terminus, VH2-scFv linker- VL2, (ii) the variableheavy domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker, and (iii) the variable light domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker; or (i) the anti-NKp46 scFv comprises, from N-terminus to C-terminus, VL2-scFv linker- VH2, (ii) the variable light domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker, and (iii) the variable heavy domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker.[0U1] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0112] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0113] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0114] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0115] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0116] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0117] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions ofS239D / I332E, wherein numbering is according to EU numbering.

[0118] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0119] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0120] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0121] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0122] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0123] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0124] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421 D / E233P / L234 V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

[0125] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0126] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0127] In another aspect, an expression vector comprising the nucleic acids (as described above)is provided.

[0128] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0129] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0130] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0131] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-first linker-scFv- second linker-CH2-CH3, wherein the VH1 is a first variable heavy domain, the scFv is an anti- NKp46 scFv, and the CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N- terminus to C-terminus, a VH2-CHl-hinge-CH2-CH3, wherein the VH2 is a second variable heavy domain and the CH2-CH3 is a second Fc domain; and (c) a common light chain comprising, from N-terminus to C-terminus, a VL-CL, wherein: (i) the VL is a variable light domain and the CL is a light chain constant domain, (ii) the first variable heavy VH1 domain and the variable light VL domain form a first MICA / B antigen binding domain, and (iii) the second variably heavy VH2 domain and the variable light VL domain form a second MICA / B antigen binding domain.

[0132] In a further embodiment and in accordance with the above, the first and / or second MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L 1 , (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11_1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B] H2 D94837 1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7[MICA / B]_H1_D1O3388_1C7 [MICA / B]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of DI 05317 1 A2 [MICA / B]_H0_D105317_l A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1A2 [MICA / B]_H1_D1O5317_1A2 [MICAZB]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICAZB]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O3388_1B11-2 [MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B] HO D105317 1F6 [MICA / B] LO, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 andSEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0133] In a further embodiment and in accordance with any of the above, the first and / or second MICA / B antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] H2 2E5 [MICA / B] LI, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXXfor D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2,(xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICAZB]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D 103388 1D7 [MICA / B] H2 D103388 1D7 [MICA / B] LI, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D991 6_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D1O5317_1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317 1F6 [MICA / B ]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [M1CA / B]_HO_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX andXXX for D94837_3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B] HO 3F9[MICA / B] L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0134] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and a first variable light VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46] Hl 2C10A3.372[NKp46] LI, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0135] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0136] In a further embodiment and in accordance with any of the above, the variable light domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the variable heavy domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0137] In a further embodiment and in accordance with any of the above, the heterodimeric antibody comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence, wherein the first, second, and third amino acid sequences are selected from the group including: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47438, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47439, as depicted inFigure 33.

[0138] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0139] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0140] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0141] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0142] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0143] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0144] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0145] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0146] In a further embodiment and in accordance with the above, the set of heterodimerizationvariants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0147] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0148] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0149] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0150] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0151] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0152] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0153] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0154] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0155] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0156] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein theheterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0157] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0158] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-first linker-scFv- second linker-CH2-CH3, wherein the VH1 is a first variable heavy domain, the scFv is an anti- MICA / B scFv, and the CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge-CH2-CH3, wherein the VH2 is a second variable heavy domain and the CH2-CH3 is a second Fc domain; and (c) a common light chain comprising, from N-terminus to C-terminus, a VL-CL, wherein: (i) the VL is a variable light domain and the CL is a light chain constant domain, (ii) the first variable heavy VH1 domain and the variable light VL domain form a first NKp46 antigen binding domain, and (iii) the second variably heavy VH2 domain and the variable light VL domain form a second NKp46 antigen binding domain.

[0159] In a further embodiment and in accordance with the above, the first and / or second NKp46 antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0160] In a further embodiment and in accordance with any of the above, the first and / or second NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0161] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and a first variable light VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXXfor vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICAZB]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICAZB]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICAZB]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B] _L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD103388JD7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136 2C11 [MICA / B] H2 D99136 2C 11 [MICA / B] L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_HO_D1O5317 1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F6 [MICA / B]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8[MICAZB]_H0_D88487_2A8 [MICA / B]_LO, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0162] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837JE11 1 [MICA / B]_HO_D94837_1E11_1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] Hl D94837 1E11 1 [MICA / B] LI, (iii) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7[MICAZB]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICAZB]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B] Hl D103388 1C7 [MICA / B] _L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for DI 05317 1 A2 [MICA / B]_H0_D105317_l A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317 1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0,(xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B]_HO_D94837_1D8 [MICAZB]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852 2D4 [MICA / B] HO D94852 2D4 [MICA / B] LO, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837 3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0163] In a further embodiment and in accordance with any of the above, the variable light domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the variable heavy domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0164] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0165] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0166] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0167] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0168] In a further embodiment and in accordance with the above, the one or more FcyRIIIA(CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298 A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0169] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0170] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0171] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0172] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0173] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0174] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0175] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0176] In a further embodiment and in accordance with the above, the one or more pl variantsare N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0177] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421 D / E233P / L234 V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

[0178] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0179] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0180] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0181] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0182] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0183] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0184] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -hinge-first linker- VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain; (b) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, and wherein the VH1 and VL1 form MICA / B antigen binding domains; and (c) a second monomer comprising, from N-terminus to C-terminus, an anti-NKp46 scFv and a second Fc domain, wherein the scFv is covalently attached to the N-terminus of the second Fc domain using a domain linker.

[0185] In a further embodiment and in accordance with the above, the anti-NKp46 scFv comprises a second variable heavy VH2 domain, an scFv linker, and a second variable light VL2 domain.

[0186] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0187] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46] H NKp46-A[NKp46] L, as depicted in Figures 23 and 24.

[0188] In a further embodiment and in accordance with any of the above, each of the MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair, wherein the set of vhCDRl-3 and vlCDRl-3 is selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX- XXX for vlCDR 1-3 of D94837_1E11_1 [MICA / B ]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837JE11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX- XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B] Hl D94837 1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5[MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of2E5 [MICA / B] H2 2E5 [MICA / B] L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136_2F7 [MICA / B]_HI_D99I36_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of DI03388 1D7[MICA / B]_HO_D1O3388_1D7 [MICA / B]_LO, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of DI 05317 1 A2 [MICA / B]_H2_D105317_l A2 [MICA / B]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D105317_IA2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICAZB]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_DI03388_lBl 1-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_HO_D1O5317 1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICAZB]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B] HO D94837 1D8 [MICA / B] LO, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837_lEl [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICAZB]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0189] In a further embodiment and in accordance with any of the above, each of the MICA / B antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1[MICA / B]_HO_D94837_1E11_1 [MICA / B]_LO, (ii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H2_D94837_1E1 I I [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] H2 D94837 1E11 1 [MICA / B] L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [M1CA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1 , (xxx) SEQ ID Nos:XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B] _L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317 1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXXfor D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICAZB]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388JB11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317JC8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317 1F6 [MICA / B ]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICAZB]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXXand XXX for 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0190] In a further embodiment and in accordance with any of the above, the heterodimeric antibody comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence, wherein the first, second, and third amino acid sequences are selected from the group including: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47442, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47443, as depicted in Figure 34.

[0191] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0192] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0193] In a further embodiment and in accordance with any of the above, the first and second linkers are each domain linkers.

[0194] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0195] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0196] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0197] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D :WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0198] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0199] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0200] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0201] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0202] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0203] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0204] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0205] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0206] In a further embodiment and in accordance with any of the above, the first and secondmonomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0207] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0208] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0209] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0210] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0211] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0212] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -hinge-first linker- VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain; (b) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, and wherein the VH1 and VL1 form NKp46 antigen binding domains; and (c) a second monomer comprising, from N-terminus to C-terminus, an anti-MICA / B scFv and a second Fc domain, wherein the scFv is covalently attached to the N-terminus of the second Fc domain using a second linker.

[0213] In a further embodiment and in accordance with the above, the anti-MICA / B scFv comprises a second variable heavy VH2 domain, an scFv linker, and a second variable light VL2 domain.

[0214] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1[MICA / B]_LO, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX- XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7[MICAZB]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1A2 [MICA / B]_H0_D105317_1A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JA2 [MICA / B]_H1_D1O5317_1A2 [MICAZB]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B] HO DI 03388 IB 11 -2 [MICA / B] _L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of DI 05317 1 C8 [MICA / B]_HO_D1O5317 1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JF7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837JD8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9[MICA / B] HO 13 A9 [MICA / B] LO, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0215] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1[MICAZB]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] H2 D94837 1E11 1 [MICA / B] LI, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7[MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX forD103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_LO, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B] H2 DI 03388 1C7 [MICA / B] L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317 1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for DI 05317JA2 [MICA / B]_H1_D1O5317_1 A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D1O5317_1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317 1F6 [MICA / B ]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837_1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9[MICA / B]_HO_D94837_1D9 [MICA / B]_LO, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487 2A8 [MICA / B] HO D88487 2A8 [MICA / B] LO, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0216] In a further embodiment and in accordance with any of the above, each of the NKp46 antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair, wherein the set of vhCDRl-3 and vlCDRl-3 is selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX- XXX for vICDR 1-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of NKp46- A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0217] In a further embodiment and in accordance with any of the above, each of the NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0218] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0219] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0220] In a further embodiment and in accordance with any of the above, the first and second linkers are each domain linkers.

[0221] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0222] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0223] In a further embodiment and in accordance with the above, the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0224] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0225] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0226] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0227] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0228] In a further embodiment and in accordance with any of the above, the first and secondvariant Fc domains further comprise one or more ablation variants.

[0229] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0230] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0231] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0232] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

[0233] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0234] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0235] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0236] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0237] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0238] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0239] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-hinge-CH2-CH3- domain linker-scFv, wherein VH1 is a first variable heavy domain, scFv is an anti-NKp46 scFv, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N-terminus to C- terminus, a VH2-CHl-hinge-CH2-CH3, wherein CH2-CH3 is a second Fc domain; and (c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, wherein: (i) the VH1 and the VL1 form a first MICA / B antigen binding domain, (ii) the VH2 domain and the VL1 form a second MICA / B antigen binding domain, and (iii) the anti-NKp46 scFv comprises a VH3 domain, a scFv linker, and a VL2 domain.

[0240] In a further embodiment and in accordance with the above, the first and / or second MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E1 1 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12[MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B] H1 D99136 2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B ]_HO_D1O3388_1C7 [MICAZB]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B] H1 D103388 1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H0_D103388_lD7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H0_D 105317 1 A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B] Hl D105317 1A2 [MICA / B] LI, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D105317 1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9[MICAZB]_LO, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2D4 [MICAZB]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B] HO D94852 2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0241] In a further embodiment and in accordance with any of the above, the first and / or second MICA / B antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ IDNos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B] HO D94852 2E12 [MICA / B] LO, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317_1 A2 [MICA / B ]_H0_D105317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX forD105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B] H2 D99136 2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C 11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D1O5317_1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317JF6 [MICA / B ]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837_1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837JD8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837JE1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0242] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy chain VH1 domain andfirst variable light chain VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_ NKp46- A[NKp46] L, as depicted in Figures 23 and 24.

[0243] In a further embodiment and in accordance with any of the above, the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0244] In a further embodiment and in accordance with any of the above, the variable light domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the variable heavy domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0245] In a further embodiment and in accordance with any of the above, the heterodimeric antibody comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence, wherein the first, second, and third amino acid sequences are selected from the group including: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47446, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47447, as depicted in Figure 35.

[0246] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0247] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0248] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0249] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

[0250] In a further embodiment and in accordance with the above, the one or more FcyRIIIA(CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298 A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0251] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIIA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0252] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

[0253] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0254] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0255] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0256] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0257] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0258] In a further embodiment and in accordance with the above, the one or more pl variantsare N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0259] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421 D / E233P / L234 V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

[0260] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0261] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0262] In another aspect, an expression vector comprising the nucleic acids (as described above) is provided.

[0263] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0264] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0265] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0266] In another aspect, the present disclosure provides a heterodimeric antibody, comprising: (a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-hinge-CH2-CH3- domain linker-scFv, wherein VH1 is a first variable heavy domain, scFv is an anti-MICA / B scFv, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge-CH2-CH3, wherein CH2-CH3 is a second Fc domain; and (c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, wherein: (i) the VH1 and the VL1 form a first NKp46 antigen binding domain, (ii) the VH2 domain and the VL1 form a second NKp46antigen binding domain, and (iii) the anti-NKp46 scFv comprises a VH3 domain, a scFv linker, and a VL2 domain.

[0267] In a further embodiment and in accordance with the above, the first and / or second NKp46 antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

[0268] In a further embodiment and in accordance with any of the above, the first and / or second NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

[0269] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy chain VH1 domain and first variable light chain VL1 domain pair selected from the group including: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837_1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837JE11 1[MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ IDNOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICAZB]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICAZB]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICAZB] H1 D103388 1C7 [MICA / B]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICAZB]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICAZB]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B] H2 DI 03388 1D7 [MICA / B] LI, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_H0_D105317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JA2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 J A2 [MICA / B]_H2_D105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D 105317 1 C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7[MICAZB]_LO, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICAZB]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B] HO D94837 1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1 -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

[0270] In a further embodiment and in accordance with any of the above, the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group including: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX forD94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] HO 2E5 [MICA / B] LO, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L 1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [M1CA / B]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos:XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ IDNos: XXX and XXX for D105317 1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2[MICA / B] H2 D105317 1A2 [MICA / B] LI, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317JB6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317 1F6 [MICA / B ]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICAZB]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[M1CA / B]_HO_3F9[M1CA / B]_LO, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICAZB]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

[0271] In a further embodiment and in accordance with any of the above, the variable light domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker, or the variable heavy domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

[0272] In a further embodiment and in accordance with any of the above, the scFv linker is a charged scFv linker.

[0273] In a further embodiment and in accordance with the above, the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

[0274] In a further embodiment and in accordance with any of the above, the first and second Fc domains are each variant Fc domains.

[0275] In a further embodiment and in accordance with the above, the first and / or second variant Fc domains comprise one or more FcyRIIlA (CD16a) binding variant substitutions.

[0276] In a further embodiment and in accordance with the above, the one or more FcyRIIlA (CD16a) binding variant substitutions are selected from the group including: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298 A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

[0277] In a further embodiment and in accordance with the above, the first and second variant Fc domains comprise a set of FcyRIIlA (CD 16a) binding variant substitutions selected from the group including: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

[0278] In a further embodiment and in accordance with any of the above, the first and / or second variant Fc domains comprise the FcyRIIlA (CD16a) binding variant substitutions ofS239D / I332E, wherein numbering is according to EU numbering.

[0279] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group including those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

[0280] In a further embodiment and in accordance with the above, the set of heterodimerization variants is selected from the group including: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

[0281] In a further embodiment and in accordance with any of the above, the first and second variant Fc domains further comprise one or more ablation variants.

[0282] In a further embodiment and in accordance with the above, the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0283] In a further embodiment and in accordance with any of the above, one of the first or second variant Fc domain comprises one or more pl variants.

[0284] In a further embodiment and in accordance with the above, the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0285] In a further embodiment and in accordance with any of the above, the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421 D / E233P / L234 V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

[0286] In a further embodiment and in accordance with any of the above, the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

[0287] In another aspect, a nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody (as described above) is provided.

[0288] In another aspect, an expression vector comprising the nucleic acids (as described above)is provided.

[0289] In another aspect, a host cell transformed with the expression vector (as described above) is provided.

[0290] In another aspect, a method of making a heterodimeric antibody is provided, the method comprising: (a) culturing the host cell (as described above) under conditions wherein the heterodimeric antibody is expressed, and (b) recovering the heterodimeric antibody.

[0291] In another aspect, the present disclosure provides a method of treating cancer, comprising: administering to a human subject an antibody comprising: (i) a MICA / B antigen binding domain (as described above), (ii) a NKp46 antigen binding domain (as described above), or (iii) a heterodimeric antibody (as described above) to the human subject.

[0292] In a further embodiment and in accordance with the above, the method can further comprise administering an IL-15-Fc fusion protein to the human subject.

[0293] In a further embodiment and in accordance with the above, the IL- 15 Fc fusion protein comprises the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP24045.

[0294] In another aspect, the present disclosure provides a method of blocking MICA / B shedding by NK cells in a human subject, the method comprising: administering to the human subject a therapeutically effective amount of an antibody comprising: (i) a MICA / B antigen binding domain (as described above), or (ii) a heterodimeric antibody (as described above) to the human subject.

[0295] In a further embodiment and in accordance with the above, CD16 and / or NKG2D is activated on the NK cells.

[0296] In a further embodiment and in accordance with any of the above, the method further comprises administering an IL-15-Fc fusion protein to the human subject.

[0297] In a further embodiment and in accordance with the above, the IL- 15 Fc fusion protein comprises the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP24045.

[0298] In another aspect, the present disclosure provides a heterodimeric antibody comprising: (a) a first monomer; (b) a second monomer; and (c) a third monomer, wherein the first monomer, the second monomer, and the third monomer comprise: (i) the amino acid sequences of SEQ IDNOs: XXX-XXX of XENP44543, respectively, (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP45903, respectively, (iii) the amino acid sequences of SEQ ID NOs: XXX- XXX of XENP45902, respectively, (iv) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP44549, respectively, (v) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP44551, respectively, (vi) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP44553, respectively, or (vii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP44552, respectively, as depicted in Fig. 71.

[0299] In another aspect, the present disclosure provides a nucleic acid composition comprising: (a) a first nucleic acid encoding the first monomer of a heterodimeric antibody (as described above), (b) a second nucleic acid encoding the second monomer of a heterodimeric antibody (as described above), and (c) a third nucleic acid encoding the third monomer of a heterodimeric antibody (as described above).

[0300] In another aspect, the present disclosure provides an expression vector composition comprising: (a) a first expression vector comprising the first nucleic acid encoding the first monomer of a heterodimeric antibody (as described above), (b) a second expression vector comprising the second nucleic acid encoding the second monomer of a heterodimeric antibody (as described above), and (c) a third expression vector comprising the third nucleic acid encoding the third monomer of a heterodimeric antibody (as described above).

[0301] In another aspect, the present disclosure provides a host cell comprising an expression vector composition (as described above).

[0302] In another aspect, the present disclosure provides a method of making a heterodimeric antibody, comprising: (a) culturing a host cell (as described above) under conditions wherein the heterodimeric antibody is expressed; and (b) recovering the heterodimeric antibody.

[0303] In another aspect, the present disclosure provides a method of treating cancer, comprising: administering to a human subject an antibody comprising a heterodimeric antibody (as described above).BRIEF DESCRIPTION OF THE DRAWINGS

[0304] The novel features of the invention are set forth with particularity in the appended claims.A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Fig.,” “FIG.,” “Figure,” “Figures,” “Figs.,” and “FIGs .” herein) of which.

[0305] Fig. 1 depicts the sequences for human and cynomolgus MICA. Such MICA are useful for the development of cross-reactive MICA antigen binding domains for ease of clinical development. The following alleles of MICA are known: MICA*001, MICA*002, MICA*004, MICA*005, MICA*006, MICA*007, MICA*008, MICA*009, MICA*010, MICA*011, MICA*012, MICA*013, MICA*014, MICA*015, MICA*016, MICA*017, MICA*018, MICA*019, MICA*020, MICA*022, MICA*023, MICA*024, MICA*025, MICA*026, MICA*027, MICA*028, MICA*029, MICA*030, MICA*031, MICA*032, MICA*033, MICA*034, MICA*035, MICA*036, MICA*037, MICA*038, MICA*039, MICA*040, MICA*041, MICA*042, MICA*043, MICA*044, MICA*045, MICA*046, MICA*047, MICA*048, MICA*049, MICA*050, MICA*051, MICA*052, MICA*053, MICA*054, MICA*055 and MICA*056.

[0306] Fig. 2 depicts the sequences for human and cynomolgus MICB. Such MICB are useful for the development of cross-reactive MICA antigen binding domains for ease of clinical development. The following alleles of MICB are known: MICB*001, MICB*002, MICB*003, MICB*004, MICB*005, MICB*006, MICB*007, MICB*008, MICB*009N, MICB*010, MICB*011, MICB*012, MICB*013, MICB*014, MICB*015, MICB*016, MICB*018, MICB*019, MICB*020, MICB*021N and MICB*022. MICB*009N and MICB*021N are null alleles which are not expressed. The three most common MICB alleles in the human population could be MICB*005, MICB*004, and MICB*002.

[0307] Fig. 3 depicts the sequences for human, mouse, and cynomolgus NKp46. Such NKp46 are useful for the development of cross-reactive NKp46 antigen binding domains for ease of clinical development.

[0308] Fig. 4 (Figs. 4A-4F) depicts useful pairs of heterodimerization variant sets (including skew and pl variants). In Fig. 4F, there are variants for which there are no corresponding “monomer 2” variants. Such variants are pl variants that can be used alone on either monomer of a NKp46 x MICA / B bsAb, or included, for example, on the non-scFv side of a format thatutilizes an scFv as a component and an appropriate charged scFv linker can be used on the second monomer that utilizes an scFv as a binding domain. Suitable charged linkers are shown in Fig. 8.

[0309] Fig. 5 depicts a list of isosteric variant antibody constant regions and their respective substitutions. pl_(-) indicates lower pl variants, while pl_(+) indicates higher pl variants. These variants can be optionally and independently combined with other variants, including heterodimerization variants, outlined herein.

[0310] Fig. 6 depicts useful ablation variants that ablate FcyR binding (also referred to as “knockouts” or “KO” variants). In some embodiments, such ablation variants are included in the Fc domain of both monomers of the subject antibody described herein. In other embodiments, the ablation variants are only included on only one variant Fc domain.

[0311] Fig. 7 depicts useful variants that enhance FcyR binding (also referred to as ADCC- enhanced variants). In some embodiments, such ADCC-enhanced variants are included in the Fc domain of both monomers of the subject antibody described herein. In other embodiments, the variants are only included on only one variant Fc domain.

[0312] Fig. 8 depicts a number of charged scFv linkers that find use in increasing or decreasing the pl of the subject heterodimeric NKp46 x MICA / B bsAbs that utilize one or more scFv as a component, as described herein. The (+H) positive linker finds particular use herein. A single prior art scFv linker with a single charge is referenced as “Whitlow”, from Whitlow et al., Protein Engineering 6(8): 989-995 (1993). It should be noted that this linker was used for reducing aggregation and enhancing proteolytic stability in scFvs. Such charged scFv linkers can be used in any of the subject antibody formats disclosed herein that include scFvs (e.g., 1 + 1 Fab-scFv-Fc and 2 + 1 Fab2-scFv-Fc formats).

[0313] Fig. 9 depicts a number of exemplary domain linkers. In some embodiments, these linkers find use linking a single-chain Fv to an Fc chain. In some embodiments, these linkers may be combined in any orientation. For example, a GGGGS linker may be combined with a “lower half hinge” linker at the N-terminus or at the C-terminus.

[0314] Fig. 10 shows a particularly useful embodiment of the heterodimeric Fc domains (i.e.CH2-CH3 in this embodiment) of the NKp46 x MICA / B bsAbs of the invention.

[0315] Fig. 11 depicts various heterodimeric skewing variant amino acid substitutions that can be used with the heterodimeric antibodies described herein.

[0316] Fig. 12 (Figs. 12A-12E) shows the sequences of heterodimeric NKp46 x MICA / B bsAb backbones with ablated effector function. Heterodimeric Fc backbone 1 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 2 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K skew variant on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 3 is based on human IgGl (356E / 358M allotype), and includes the L368E / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K skew variant on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 4 is based on human IgGl (356E / 358M allotype), and includes the K360E / Q362E / T41 IE skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the D401K skew variant on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 5 is based on human IgGl (356D / 358L allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 6 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and N297A variant that removes glycosylation on both chains. Heterodimeric Fc backbone 7 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Qskew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and N297S variant that removes glycosylation on both chains. Heterodimeric Fc backbone 8 is based on human IgG4, and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the S228P (according to EU numbering, S241P in Kabat) variant that ablates Fab arm exchange (as is known in the art) on both chains. Heterodimeric Fc backbone 9 is based on human IgG2, and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain. Heterodimeric Fc backbone 10 is based on human IgG2, and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the S267K ablation variant on both chains. Heterodimeric Fc backbone 11 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and M428L / N434S Xtend variants on both chains. Heterodimeric Fc backbone 12 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants and P217R / P229R / N276K pl variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants on both chains. Heterodimeric Fc backbone 13 is based on human IgGl (356E / 358M allotype), and includes the T366W skew variant on a first heterodimeric Fc chain, the T366S / L368A / Y407V skew variants and H435R / Y436F purification variants on a second heterodimeric Fc chain, and the L234A / L235A / D265S ablation variants on both chains. Heterodimeric Fc backbone 14 is based on human IgGl (356E / 358M allotype), and includes the T366W skew variant on a first heterodimeric Fc chain, the T366S / L368A / Y407V skew variants and H435R / Y436F purification variants on a second heterodimeric Fc chain, and the L234A / L235A / D265S ablation variants and M252Y / S254T / T256E halfdife extension variants on both chains. Heterodimeric Fc backbone 15 is based on human IgGl (356D / 358L allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, theS364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and M428L / N434S Xtend variants on both chains. Heterodimeric Fc backbone 16 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and M428L / N434A Xtend variants on both chains. Heterodimeric Fc backbone 17 is based on human IgGl (356D / 358L allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and M428L / N434A Xtend variants on both chains.

[0317] Included within each of these backbones are sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition or as an alternative to the skew, pl and ablation variants contained within the backbones of this Figure. Additionally, the backbones depicted herein may include deletion of the C-terminal glycine (K446_) and / or lysine (K447_). The C-terminal glycine and / or lysine deletion may be intentionally engineered to reduce heterogeneity or in the context of certain bispecific formats, such as the mAb-scFv format. Additionally, C-terminal glycine and / or lysine deletion may occur naturally for example during production and storage.

[0318] Fig. 13 (Figs. 13A-13C) shows the sequences of several useful heterodimeric NKp46 x MICA / B bsAb backbones based on human IgGl and having WT effector function.Heterodimeric Fc backbone 1 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain. Heterodimeric Fc backbone 2 is based on human IgGl (356E / 358M allotype), and includes theL368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K skew variant on a second heterodimeric Fc chain. Heterodimeric Fc backbone 3 is based on human IgGl (356E / 358M allotype), and includes the L368E / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K skew variant on a second heterodimeric Fc chain. Heterodimeric Fc backbone 4 is based on human IgGl (356E / 358M allotype), and includes the K360E / Q362E / T41 IE skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the D401K skew variant on a second heterodimeric Fc chain. Heterodimeric Fc backbone 5 is based on human IgGl (356D / 358L allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain. Heterodimeric Fc backbone 6 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and N297A variant that removes glycosylation on both chains. Heterodimeric Fc backbone 7 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and N297S variant that removes glycosylation on both chains. Heterodimeric Fc backbone 8 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and M428L / N434S Xtend variants on both chains. Heterodimeric Fc backbone 9 is based on human IgGl (356D / 358L allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and the E233P / L234V / L235A / G236del / S267K ablation variants and M428L / N434S Xtend variants on both chains. Heterodimeric Fc backbone 10 is based on human IgGl (356E / 358M allotype), and includes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and M428L / N434A Xtend variants on both chains. Heterodimeric Fc backbone 11 is based on human IgGl (356D / 358L allotype), andincludes the L368D / K370S skew variants and the Q295E / N384D / Q418E / N421D pl variants on a first heterodimeric Fc chain, the S364K / E357Q skew variants on a second heterodimeric Fc chain, and M428L / N434A Xtend variants on both chains.

[0319] Included within each of these backbones are sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition or as an alternative to the skew, pl and ablation variants contained within the backbones of this Figure. Additionally, the backbones depicted herein may include deletion of the C-terminal glycine (K446_) and / or lysine (K447_). The C-terminal glycine and / or lysine deletion may be intentionally engineered to reduce heterogeneity or in the context of certain bispecific formats, such as the mAb-scFv format. Additionally, C-terminal glycine and / or lysine deletion may occur naturally for example during production and storage.

[0320] Fig. 14 (Figs. 14A-14C) shows the sequences of several useful heterodimeric NKp46 x MICA / B bsAb backbones based on human IgGl and having enhanced ADCC function. The sequences here are based on heterodimeric Fc backbone 1 in Figure 13, although the ADCC variants in Figure 7 may also be included in any of the other heterodimeric Fc backbones in Figure 13. ADCC-enhanced Heterodimeric Backbone 1 includes S239D / I332E on both the first and the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 2 includes S239D on both the first and the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 3 includes I332E on both the first and the second heterodimeric Fc chain. ADCC- enhanced Heterodimeric Backbone 4 includes S239D / I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 5 includes S239D on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 6 includes I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 7 includes S239D / I332E on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 8 includes S239D on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 9 includes I332E on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 10 includesS239D / I332E on the first heterodimeric Fc chain and S239D on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 11 includes S239D / I332E on the first heterodimeric Fc chain and I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 12 includes S239D on the first heterodimeric Fc chain and S239D / I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 13 includes I332E on the first heterodimeric Fc chain and S239D / I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 14 includes S239D on the first heterodimeric Fc chain and I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 15 includes I332E on the first heterodimeric Fc chain and S239D on the second heterodimeric Fc chain.

[0321] Included within each of these backbones are sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl. That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition or as an alternative to the skew, pl and ablation variants contained within the backbones of this Figure. Additionally, the backbones depicted herein may include deletion of the C-terminal glycine (K446_) and / or lysine (K447_)- The C-terminal glycine and / or lysine deletion may be intentionally engineered to reduce heterogeneity or in the context of certain bispecific formats, such as the mAb-scFv format. Additionally, C-terminal glycine and / or lysine deletion may occur naturally for example during production and storage.

[0322] Fig. 15 (Figs. 15A-15C) shows the sequences of several useful heterodimeric NKp46 x MICA / B bsAb backbones based on human IgGl and having enhanced ADCC function and enhanced serum half-life. The sequences here are based on heterodimeric Fc backbone 8 in Figure 13, although the ADCC variants in Figure 7 may also be included in any of the other heterodimeric Fc backbones in Figure 13. ADCC-enhanced Heterodimeric Backbone 1 w / Xtend includes S239D / I332E on both the first and the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 2 w / Xtend includes S239D on both the first and the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 3 w / Xtend includes I332E onboth the first and the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 4 w / Xtend includes S239D / I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 5 w / Xtend includes S239D on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 6 w / Xtend includes I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 7 w / Xtend includes S239D / I332E on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 8 w / Xtend includes S239D on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 9 w / Xtend includes I332E on the first heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 10 w / Xtend includes S239D / I332E on the first heterodimeric Fc chain and S239D on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 11 w / Xtend includes S239D / I332E on the first heterodimeric Fc chain and I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 12 w / Xtend includes S239D on the first heterodimeric Fc chain and S239D / I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 13 w / Xtend includes I332E on the first heterodimeric Fc chain and S239D / I332E on the second heterodimeric Fc chain. ADCC-enhancedHeterodimeric Backbone 14 w / Xtend includes S239D on the first heterodimeric Fc chain and I332E on the second heterodimeric Fc chain. ADCC-enhanced Heterodimeric Backbone 15 w / Xtend includes I332E on the first heterodimeric Fc chain and S239D on the second heterodimeric Fc chain.

[0323] Included within each of these backbones are sequences that are 90, 95, 98 and 99% identical (as defined herein) to the recited sequences, and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgGl. That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition or as an alternative to the skew, pl and ablation variants contained within the backbones of this Figure. Additionally, the backbones depicted herein may include deletion of the C-terminal glycine (K446 ) and / or lysine (K447_)- The C-terminal glycine and / or lysine deletion may be intentionally engineered to reduce heterogeneity or in the context of certain bispecific formats, such as the mAb-scFv format. Additionally, C-terminal glycine and / or lysine deletion may occur naturally for example during production and storage.

[0324] Fig. 16 (Figs. 16A-16G) depicts illustrative sequences of heterodimeric NKp46 x MICA / B bsAb backbone for use in the 2 + 1 mAb-scFv format. It should be noted that any of the additional backbones depicted in Figs. 12-15 may be adapted for use in the 2 + 1 mAb-scFv format with or without including K447_ on one or both chains.

[0325] Fig. 17 depicts sequences for “CHI” that find use in embodiments of NKp46 x MICA / B bsAbs.

[0326] Fig. 18 depicts sequences for “hinge” that find use in embodiments of NKp46 x MICA / B bsAbs.

[0327] Fig. 19 depicts the constant domain of the cognate light chains which find use in the subject NKp46 x MICA / B bsAbs that utilize a Fab binding domain.

[0328] Fig. 20 depicts soluble MICA / B (sMICA / B) binding NKG2D receptor on NK cells inhibiting signaling. MICA / B bsAbs of the invention may engage cell surface MICA / B and prevent shedding as soluble MICA / B.

[0329] Fig. 21 (Figs. 21A-21S) depicts the variable heavy and variable light chain sequences for novel MICA / B binding domains which may find use in the invention. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 2, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems. Furthermore, as for all the sequences in the Figures, these VH and VL sequences can be used either in a scFv format or in a Fab format.

[0330] Fig. 22 (Figs. 22A and 22B) depicts the variable heavy and variable light chain sequences for additional MICA / B binding domains which may find use in the invention. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 2, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems. Furthermore, as for all the sequences in the Figures, these VH and V sequences can be used either in a scFv format or in a Fab format.

[0331] Fig. 23 depicts the variable heavy and variable light chain sequences for 2C10A3.372, a novel phage-derived NKp46 binding domain. CDRs are underlined and slashes indicate theborder(s) between the variable regions and constant domain. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 2, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems. Furthermore, as for all the sequences in the Figures, these VH and VL sequences can be used either in a scFv format or in a Fab format.

[0332] Fig. 24 depicts the variable heavy and variable light chain sequences for additional NKp46 binding domains which may find use in the invention. CDRs are underlined and slashes indicate the border(s) between the variable regions and constant domain. As noted herein and is true for every sequence herein containing CDRs, the exact identification of the CDR locations may be slightly different depending on the numbering used as is shown in Table 2, and thus included herein are not only the CDRs that are underlined but also CDRs included within the VH and VL domains using other numbering systems. Furthermore, as for all the sequences in the Figures, these VH and VL sequences can be used either in a scFv format or in a Fab format.

[0333] Fig. 25 (Figs. 25A-25E) depicts a few of the formats of the present invention. Fig. 25A depicts the “1 + 1 FabxscFv” format, with a first Fab arm binding a first antigen and a second scFv arm binding second antigen. The 1 + 1 Fab-scFv-Fc format comprises a first monomer comprising a first heavy chain variable region (VH1) covalently attached to the N-terminus of a first heterodimeric Fc backbone (optionally via a linker), a second monomer comprising a singlechain Fv covalently attached to the N-terminus of a second corresponding heterodimeric Fc backbone (optionally via a linker), and a third monomer comprising a light chain variable region attached covalently to a light chain constant domain, wherein the light chain variable region is complementary to the VH1. Fig. 25B depicts the “1 + 1 emptyxFab-scFv” format, with a first Fab arm binding a first antigen and a second scFv arm binding a second antigen. The 1 + 1 empty x Fab-scFv format comprises a first monomer comprising a first heterodimeric Fc backbone, a second monomer comprising a heavy chain variable region (VH1) covalently attached (optionally via a linker) to a single-chain Fv covalently attached (optionally via a linker) to the N-terminus of a second corresponding heterodimeric Fc backbone, and a third monomer comprising a light chain variable region attached covalently to a light chain constant domain, wherein the light chain variable region is complementary to the VH1. Fig. 25C depicts the “2 + 1FabxFab-scFv” format, with a first Fab arm and a second Fab-scFv arm, wherein the Fabs bind a first antigen and the scFv binds second antigen. The 2 + 1 FabxFab-scFv format comprises a first monomer comprising a first heavy chain variable region (VH1) covalently attached to the N- terminus of a first heterodimeric Fc backbone (optionally via a linker), a second monomer comprising the VH1 covalently attached (optionally via a linker) to a single-chain Fv covalently attached (optionally via a linker) to the N-terminus of a second corresponding heterodimeric Fc backbone, and a third monomer comprising a light chain variable region attached covalently to a light chain constant domain, wherein the light chain variable region is complementary to the VH1. Fig. 25D depicts the “2 + 1 Fab2 x scFv” format, with a first Fab-Fab arm and a second scFv arm, wherein the Fabs bind a first antigen and the scFv binds second antigen. The 2 + 1 Fab2 x scFv format comprises a first monomer comprising a first heavy chain variable region (VH1) covalently attached to a CHI domain covalently attached to a second VH1 (optionally via a linker) that is further covalently attached to the N-terminus of a first heterodimeric Fc backbone (optionally via a linker), a second monomer comprising a single-chain Fv covalently attached (optionally via a linker) to the N-terminus of a second corresponding heterodimeric Fc backbone, and a third monomer comprising a light chain variable region attached covalently to a light chain constant domain, wherein the light chain variable region is complementary to the VH1. Fig. 25E depicts the “2 + 1 mAb-scFv” format, with a first Fc comprising an N-terminal Fab arm binding a first antigen and a second Fc comprising an N-terminal Fab arm binding the first antigen and a C-terminal scFv binding a second antigen. The 2 + 1 mAb-scFv format comprises a first monomer comprising VHl-CHl-hinge-CH2-CH3, a second monomer comprising VHl-CHl-hinge-CH2-CH3-scFv, and a third monomer comprising VL-CL. The VL pairs with the first and second VH1 to form binding domains with binding specificity for the first antigen. In some bsAbs, the first antigen is NKp46 and the second antigen is MICA / B; while in other bsAbs, the first antigen is MICA / B and the second antigen is NKp46.

[0334] Fig. 26 (Figs. 26A and 26B) depicts the sequences of control molecules.

[0335] Fig. 27 depicts a proposed mechanism of action for the MICA / B bsAbs of the invention. 1) the bsAb engages MICA / B and tumor antigen on cancer cells, 2) the bsAb engages and activates CD16 on NK cells, and 3) the MICA / B bound by the bsAb engages and signals via NKG2D on NK cells.

[0336] Fig. 28 (Figs. 28A-28H) depicts sequences for B7H3 antibodies comprising Fc variants to enhance ADCC (or WT effector function in the case of XENP41021).

[0337] Fig. 29 depicts a matrix of symmetric and asymmetric ADCC-enhanced Fc variants that have been engineered, as well as the corresponding Tm data, affinity data, production yield, ADCC activity and target cell killing activity. As shown, each Fc monomer (-Fc HC or +Fc-scfv- Fc) has either the S239D and I332E (V90) variants, the S239D variant alone, the I332E variant alone, or is wild-type at the 239 and 332 positions; and each test article has a different combination of these Fc monomers.

[0338] Fig. 30 depicts the range of ADCC activity of the various symmetric and asymmetric V90 variants outlined in Fig. 29. The results show a large range in levels of fold change in ADCC activity of each construct compared to wild type, with V90 having one of the highest fold changes in ADCC activity compared to WT, and the various S239D and I332E combinations showing a broad range of intermediate levels fold changes.

[0339] Fig. 31 (Figs. 31 A and 3 IB) depicts the sequences or illustrative NKp46 x MICA / B bsAbs in the 1 + 1 FabxscFv format. CDRs are underlined and slashes indicate the border(s) between the variable regions, linkers, Fc regions, and constant domains. It should be noted that the NKp46 x MICA / B bsAbs can utilize variable region, Fc region, and constant domain sequences that are 90, 95, 98 and 99% identical (as defined herein), and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In addition, each sequence outlined herein can include or exclude the M428L / N434S variants in one or preferably both Fc domains, which results in longer half-life in serum. Further, each sequence outlined herein can include or exclude S239D and / or I332E variants in one or both Fc domains, which results in enhanced ADCC.

[0340] Fig. 32 depicts the sequences or illustrative NKp46 x MICA / B bsAbs in the 1 + 1 emptyxFab-scFv format. CDRs are underlined and slashes indicate the border(s) between the variable regions, linkers, Fc regions, and constant domains. It should be noted that the NKp46 x MICA / B bsAbs can utilize variable region, Fc region, and constant domain sequences that are 90, 95, 98 and 99% identical (as defined herein), and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In addition, each sequence outlined herein can include or exclude the M428L / N434S variants in one or preferably both Fc domains, which results in longer half-life in serum. Further, each sequence outlined herein can include or exclude S239D and / or I332Evariants in one or both Fc domains, which results in enhanced ADCC.

[0341] Fig. 33 depicts the sequences or illustrative NKp46 x MICA / B bsAbs in the 2 + 1 Fab x Fab-scFv format. CDRs are underlined and slashes indicate the border(s) between the variable regions, linkers, Fc regions, and constant domains. It should be noted that the NKp46 x MICA / B bsAbs can utilize variable region, Fc region, and constant domain sequences that are 90, 95, 98 and 99% identical (as defined herein), and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In addition, each sequence outlined herein can include or exclude the M428L / N434S variants in one or preferably both Fc domains, which results in longer half-life in serum. Further, each sequence outlined herein can include or exclude S239D and / or I332E variants in one or both Fc domains, which results in enhanced ADCC.

[0342] Fig. 34 depicts the sequences or illustrative NKp46 x MICA / B bsAbs in the 2 + 1 Fab2 x scFv format. CDRs are underlined and slashes indicate the border(s) between the variable regions, linkers, Fc regions, and constant domains. It should be noted that the NKp46 x MICA / B bsAbs can utilize variable region, Fc region, and constant domain sequences that are 90, 95, 98 and 99% identical (as defined herein), and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In addition, each sequence outlined herein can include or exclude the M428L / N434S variants in one or preferably both Fc domains, which results in longer half-life in serum. Further, each sequence outlined herein can include or exclude S239D and / or I332E variants in one or both Fc domains, which results in enhanced ADCC.

[0343] Fig. 35 depicts the sequences or illustrative NKp46 x MICA / B bsAbs in the 2 + 1 mAb- scFv format. CDRs are underlined and slashes indicate the border(s) between the variable regions, linkers, Fc regions, and constant domains. It should be noted that the NKp46 x MICA / B bsAbs can utilize variable region, Fc region, and constant domain sequences that are 90, 95, 98 and 99% identical (as defined herein), and / or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions. In addition, each sequence outlined herein can include or exclude the M428L / N434S variants in one or preferably both Fc domains, which results in longer half-life in serum. Further, each sequence outlined herein can include or exclude S239D and / or I332E variants in one or both Fc domains, which results in enhanced ADCC.

[0344] Fig. 36 depicts epitope binning of novel MICAZB binding domains (as well as several prior art MICA / B binding domains).I l l

[0345] Fig. 37 shows surface MICA upregulation is inversely correlated with soluble MICA. Therefore, surface MICA was used as a readout for screening novel MICA / B binding domains for their ability to prevent MICA and MICB shedding.

[0346] Fig. 38 depicts upregulation of surface MICA*002 versus surface MICA*008 to screen MICA / B binding domains that are able to prevent shedding of multiple MICA allelic variants.

[0347] Fig. 39 depicts upregulation of surface MICB*004 versus surface MICB*005 to screen MICA / B binding domains that are able to prevent shedding of multiple MICB allelic variants.

[0348] Fig. 40 depicts upregulation of surface MICA*004 under normoxic conditions versus hypoxic conditions.

[0349] Fig. 41 depicts lysis of MCF7 target cells (4: 1 E:T) by NK cells following 72 hours treatment with the novel MICA / B binding domains.

[0350] Fig. 42 depicts production of IFNy by NK cells in co-culture with MCF7 target cells (10:1 E:T) following 24 hours treatment with the novel MICA / B binding domains.

[0351] Fig. 43 depicts blockade of soluble MICA shedding from CHO cells engineered to express MICA*004-GFP by novel MICA / B binding domains.

[0352] Fig. 44 depicts binding to MICA*004 over-expressed in A375 cell line by novel MICAZB binding domains.

[0353] Fig. 45 depicts surface upregulation of MICA*004 expressed in CHO cell line engineered to express MICA*004-GFP following treatment with novel MICA / B binding domains under normoxic conditions.

[0354] Fig. 46 depicts surface upregulation of MICA*004 expressed in CHO cell line engineered to express MICA*004-GFP following treatment with novel MICA / B binding domains under hypoxic conditions.

[0355] Fig. 47: Pan tumor TMA was stained with MICA / B antibodies showing that breast (top left panel), testis (top right panel), esophagus (bottom left panel), and stomach (bottom right panel) show tumor MICA / B expression. Pancreas, skin, lung, and ovary are additional tumor histologies showing tumor MICA / B expression (not shown).

[0356] Fig. 48 depicts MICA / B mAbs mechanisms of action. 1) ADCC, 2) NKG2D agonism,and 3) blockade of MICA and MICB cleavage.

[0357] Fig. 49 depicts tumor cell killing (Fig. 49A) and induction of ZFNy secretion (Fig. 49B) by NK cells co-cultured with A375-B2M-KO-RP tumor cell line and dose titration of MICA / B mAb alone, MICA / B mAb with blocking NKG2D mAb, RSV isotype control mAb alone, or RSV mAb with blocking NKG2D mAb.

[0358] Fig. 50 depicts blockade of soluble MICA (Fig. 50A) and blockade of soluble MICB (Fig. 50B) after incubating CHO engineered to express MICA or MICB with MICA / B mAb, RSV mAb, or batimastat.

[0359] Fig. 51 depicts population frequencies of MICA (Fig. 51A) and MICB (Fig. 51B) allelic variants.

[0360] Fig. 52 depicts ct3 domain sequence alignment to identify higher frequency MICA and MICB variants.

[0361] Fig. 53 depicts correlation between IFNy AUC and target lysis EC50 of different MICA / B mAbs.

[0362] Fig. 54 depicts target lysis (Fig. 54A) and induction of IFNy secretion (Fig. 54B) by NK cells co-cultured with MCF7-RFP cells and 1E11-1-based mAb.

[0363] Fig. 55 depicts cartoon illustrating surface MICA (MICB) density, measured via C- terminal GFP intensity, inversely correlates with the membrane MICA (MICB) cleavage.

[0364] Fig. 56 depicts upregulation of surface MICA*008 versus surface MICB*005 to screen MICA / B binding domains that are able to prevent shedding of MICA and MICB.

[0365] Fig. 57 depicts upregulation of surface MICA*002 versus surface MICB*004 to screen MICA / B binding domains that are able to prevent shedding of MICA and MICB.

[0366] Fig. 58 depicts hypothesized NKp46 x MICA / B mechanisms of action including 1) ADCC, 2) NKG2D agonism, 3) blockade of MICA and MICB cleavage, and 4) NKp46 agonism.

[0367] Fig. 59 depicts induction of IFNy secretion (Fig. 59A) and target cell lysis (Fig. 59B) by NK cells co-cultured with A375-B2M-KO-RFP cells and NKp46 x MICA / B bsAbs with WT or KO effector function with or without NKG2D antibody that blocks MICA binding to the receptor.

[0368] Fig. 60 depicts induction of fFNy secretion (Fig. 60A) and target cell lysis (Fig. 60B) by NK cells co-cultured with A375-B2M-KO-RFP cells and NKp46 x MICA / B or RSV x MICA / B bsAbs with WT or KO effector function with or without NKG2D antibody that blocks MICA binding to the receptor.

[0369] Fig. 61 depicts surface MICA density (indicative of blockade of MICA cleavage) (Fig. 61 A) and target cell lysis (Fig. 61B) after co-culturing NK cells with A375-B2M-KO-RFP cells and NKp46 x MICA / B in various formats.

[0370] Fig. 62 depicts target cell lysis after co-culturing NK cells with A375-B2M-KO-RFP cells and NKp46 x MICA / B in various formats with KO effector function.

[0371] Fig. 63: Surface MICA upregulation inversely correlates with soluble MICA. Therefore, surface MICA was used as a readout for screening novel MICA / B binding domains for their ability to prevent MICA and MICB shedding.

[0372] Fig. 64 depicts target cell lysis after co-culturing NK cells with A375-B2M-KO-RFP cells and NKp46 x MICA / B in various formats with WT (Fig. 64A) or KO (Fig. 64B) effector function.

[0373] Fig. 65 depicts induction of IFNY secretion by NK cells co-cultured with A375-B2M- KO-RFP cells and NKp46 x MICA / B bsAb without IL-15-Fc fusion (Fig. 65A) and in combination with IL-15-Fc fusion (Fig. 65B).

[0374] Fig. 66 depicts sequences for an illustrative IL-15-Fc fusion that may be combined with the NKp46 x MICA / B bsAbs of the invention.

[0375] Fig. 67 depicts NKp46 mediation of target cell lysis in the absence of CD 16 engagement. Test articles XENP43729 (B7H3 x RSV control bsAb) and XENP44543 (B7H3 x NKp46 bsAb), both having an IgGl Fc domain that is null for CD 16 binding (FcKO), were mixed with purified NK cells and added to a plate of MCF7 target cells at a 3: 1 E:T ratio. MCF7 cell lysis was measured by Incucyte at 3 -hour intervals.

[0376] Fig. 68 depicts the comparatively lower fratricide levels induced by NKp46 x B7H3 bsAbs compared to NKG2D x B7H3 bsAb XENP43933. In this experiment, NK cells were mixed with the indicated dilutions of test articles, incubated, stained with Zombie Aqua for 15 minutes and washed before analysis via flow cytometry.

[0377] Fig. 69 depicts the target cell lysis induced by B7H3 x NKp46 bsAbs of varying affinities. Test articles were mixed with purified NK cells and added to a plate of MCF7 target cells at a 3: 1 E:T ratio. MCF7 cell lysis was measured by Incucyte at 3-hour intervals. As depicted, stronger NKp46 affinity correlates with greater levels of target cell lysis.

[0378] Fig. 70 (Figs. 70A-70D) depicts the sequences for various comparator and control antibodies.

[0379] Fig. 71 (Figs. 71A-71D) depicts the sequences for several B7H3 x NKp46 antibodies of the invention.

[0380] Fig. 72 depicts binding data of MICA / B binding domains of the invention, both from an ELISA measuring the amount of soluble / shed MICAZB, as well as KD data from the Carterra® LSA.

[0381] Fig. 73 depicts the comparable binding of murine(H0L0) and humanized (HILI, H1L2, H2L1, and H2L2) variants of 1E11 and 2C 11 to CHO cells expressing MICA*004.DETAILED DESCRIPTIONI. Overview

[0382] The description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements. The section headings used herein are for organization purposes only and are not to be construed as limiting the subject matter described. While various embodiments of the invention(s) of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention(s). It should be understood that various alternatives to the embodiments of the invention(s) described herein may be employed in practicing any one of the inventions(s) set forth herein.

[0383] All patents, published patent applications, other publications, and sequences from GenBank, and other databases referred to herein are incorporated by reference in their entirety with respect to the related technology.II. Nomenclature

[0384] The antibodies provided herein are listed in several different formats. In some instances, each monomer of a particular antibody is given a unique “XENP” number, although as will be appreciated in the art, a longer sequence might contain a shorter one. For example, a “scFv-Fc” monomer of a 1 + 1 Fab-scFv-Fc format antibody may have a first XENP number, while the scFv domain itself will have a different XENP number. Some molecules have three polypeptides, so the XENP number, with the components, is used as a name. Thus, the molecule XENP46810, which is in 1 + 1 Fab-scFv-Fc format, comprises three sequences (see Fig. 31 A) a “Fab-Fc Heavy Chain” monomer (“Chain 1”); 2) a “scFv-Fc Heavy Chain” monomer (“Chain 2”); and 3) a “Light Chain” monomer (“Chain 3”) or equivalents, although one of skill in the art would be able to identify these easily through sequence alignment. These XENP numbers are in the sequence listing as well as identifiers, and used in the Figures. In addition, one molecule, comprising the three components, gives rise to multiple sequence identifiers. For example, the listing of the Fab includes, the full heavy chain sequence, the variable heavy domain sequence and the three CDRs of the variable heavy domain sequence, the full light chain sequence, a variable light domain sequence and the three CDRs of the variable light domain sequence. A Fab-scFv-Fc monomer includes a full-length sequence, a variable heavy domain sequence, 3 heavy CDR sequences, and an scFv sequence (include scFv variable heavy domain sequence, scFv variable light domain sequence and scFv linker). Note that some molecules herein with a scFv domain use a single charged scFv linker (+H), although others can be used. In addition, the naming nomenclature of particular antigen binding domains (e.g., NKp46 and MICA / B binding domains) use a “Hx.xx_Ly.yy” type of format, with the numbers being unique identifiers to particular variable chain sequences. Thus, an Fv domain of the antigen binding domain is “Hl LI,” which indicates that the variable heavy domain, Hl, was combined with the light domain LI. In the case that these sequences are used as scFvs, the designation “Hl LI,” indicates that the variable heavy domain, Hl is combined with the light domain, LI, and is in Vn-linker-VL orientation, from N- to C-terminus. This molecule with the identical sequences of the heavy and light variable domains but in the reverse order (Vi -linker-Vn orientation, from N- to C-terminus) would be designated “L1 H1.1”. Similarly, different constructs may “mix and match” the heavy and light chains as will be evident from the sequence listing and the figures.III. Definitions

[0385] In order that the application may be more completely understood, several definitions are set forth below. Such definitions are meant to encompass grammatical equivalents.

[0386] “MICA and MICB” and “MICA / B” is herein meant NKG2D ligands which can, in some instances, be upregulated in several human cancers. MICA / B are transmembrane proteins with MHC-like extracellular domains that, do not associate with beta-2 microglobulin nor present antigens. The proteins can undergo proteolytic cleavage in a multistep process and thereafter, the soluble MICA / B can bind NKG2D on NK cells. In some cases, the soluble MICA / B is shed in the blood plasma and serum in subjects with cancer. Additional information includes amino acid sequences of “MHC class I polypeptide-related sequence A,” “MIC-A” or “MICA” can be found in, for example, UniProt No. Q29983 (human), GenBank Accession Numbers NP_000238.1 (human), NP_001170990.1 (human), NP_001276081 (human), NP_001276082 (human), and NP 001276082 (human). Additional information includes amino acid sequences of “MHC class I polypeptide-related sequence B,” “MIC-B” or “MICB” can be found in, for example, UniProt No. Q29980 (human), GenBank Accession Numbers NP_001276089 (human), NP_001276090 (human), NP_005922 (human), NP_715641 (mouse), and NP_715642 (mouse). Exemplary MICA / B sequences are depicted in Figs. 1 and 2. Unless otherwise noted, references to MICA / B are to the human MICA / B sequences.

[0387] By “NKp46,” “NCR1,” “CD335,” “LY94 ,” “NK-p46,” “natural cytotoxicity triggering receptor 1” (e.g., GenBank Accession Numbers NM_004829.7 (human), NM_001145457.3 (human), NM_001145458.3 (human), NM_001242356.3 (human), NM_001242357.3 (human), NM 010746.3 (mouse), and NM 001368364.1 (mouse)), is meant a transmembrane protein belonging to the natural cytotoxicity receptor family. Exemplary NKp46 sequences are depicted in Fig. 3. Unless otherwise noted, references to NKp46 are to the human NKp46 sequences.

[0388] By “NKG2D,” “NKG2-D,” “natural killer group 2D,” “CD314,” (e.g, GenBank Accession Numbers NP_031386.2 (human), NP_001186734.1 (human), and NP_001076791.1 (mouse)), herein is meant a transmembrane protein belonging to the NKG2 family of C-type lectin-like receptors. NKG2D is a major recognition receptor for the detection and elimination of transformed and / or infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress, such as in cancer. In humans, NKG2D is expressed by NKcells, y3 T cells, and CD8+aP T cells.

[0389] By “ablation” herein is meant a decrease or removal of activity. Thus, for example, “ablating FcyR binding” means the Fc region amino acid variant has less than 50% starting binding as compared to an Fc region not containing the specific variant, with more than 70-80- 90-95-98% loss of activity being preferred, and in general, with the activity being below the level of detectable binding in a Biacore, SPR or BLI assay.

[0390] By “ADCC” or “antibody dependent cell-mediated cytotoxicity” as used herein is meant the cell-mediated reaction, wherein nonspecific cytotoxic cells that express FcyRs recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC is correlated with binding to FcyRIIIa; increased binding to Fc / RIIIa leads to an increase in ADCC activity.

[0391] By “ADCP” or antibody dependent cell-mediated phagocytosis as used herein is meant the cell-mediated reaction wherein nonspecific phagocytic cells that express Fey Rs recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell.

[0392] As used herein, the term “antibody” is used generally. Antibodies provided herein can take on a number of formats as described herein, including traditional antibodies as well as antibody derivatives, fragments and mimetics, described herein.

[0393] Traditional immunoglobulin (Ig) antibodies are “Y” shaped tetramers. Each tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one “light chain” monomer (typically having a molecular weight of about 25 kDa) and one “heavy chain” monomer (typically having a molecular weight of about 50-70 kDa).

[0394] Other useful antibody formats include, but are not limited to, the “1 + 1 Fab x scFv” (also referred to herein as the “1 + 1 Fab-scFv-Fc” or “bottle-opener” format), “1 + 1 empty x Fab- scFv” (also referred to herein as the “one-armed central-scFv” format), “2 + 1 FabxFab-scFv” (also referred to herein as the “2 + 1 Fab2-scFv-Fc” format), “2 + 1 Fab2 x scFv” (also referred to herein as the “2 + 1 stab Fab2-scFv-Fc” format), and “2 + 1 mAb-scFv” (also referred to herein as the “mAb-scFv” format) formats provided herein (see, e.g., Figs. 25A-25E). Additional useful antibody formats include, but are not limited to: “mAb-Fv,” “central-Fv,” “1 + 1 common light chain” (CLC), “2 + 1 CLC,” “one-armed scFv-mAb,” “scFv-mAb,” “dual scFv,”“bispecific mAb,” and “trident” format antibodies as depicted in Fig. 36 of U.S. Publ. App. No. 2022 / 0289839, hereby incorporated by reference in its entirety and specifically for its disclosure of antibody formats.

[0395] Antibody heavy chains typically include a vailable heavy (VH) domain, which includes vhCDRl-3, and an Fc domain, which includes a CH2-CH3 monomer. In some embodiments, antibody heavy chains include a hinge and CHI domain. Traditional antibody heavy chains are monomers that are organized, from N- to C-terminus: VH-CHl-hinge-CH2-CH3. The CH1- hinge-CH2-CH3 is collectively referred to as the heavy chain “constant domain” or “constant region” of the antibody, of which there are five different categories or “isotypes”: IgA, IgD, IgG, IgE and IgM.

[0396] In some embodiments, the antibodies provided herein include IgG isotype constant domains, which has several subclasses, including, but not limited to IgGl, IgG2, and IgG4. In the IgG subclass of immunoglobulins, there are several immunoglobulin domains in the heavy chain. By “immunoglobulin (Ig) domain” herein is meant a region of an immunoglobulin having a distinct tertiary structure. Of interest in the present invention are the heavy chain domains, including, the constant heavy (CH) domains and the hinge domains. In the context of IgG antibodies, the IgG isotypes each have three CH regions. Accordingly, “CH” domains in the context of IgG are as follows: “CHI” refers to positions 118-215 according to the EU index as in Kabat. “Hinge” refers to positions 216-230 according to the EU index as in Kabat. “CH2” refers to positions 231-340 according to the EU index as in Kabat, and “CH3” refers to positions 341- 447 according to the EU index as in Kabat. As shown in Table 1, the exact numbering and placement of the heavy chain domains can be different among different numbering systems. As shown herein and described below, the pl variants can be in one or more of the CH regions, as well as the hinge region, discussed below.

[0397] It should be noted that IgGl has different allotypes with polymorphisms at 356 (D or E) and 358 (L or M). The sequences depicted herein use the 356E / 358M allotype, however the other allotype is included herein. That is, any sequence inclusive of an IgGl Fc domain included herein can have 356D / 358L replacing the 356E / 358M allotype. It should be understood that therapeutic antibodies can also comprise hybrids of isotypes and / or subclasses. For example, as shown in US Publication 2009 / 0163699, incorporated by reference, the present antibodies, insome embodiments, include human IgGl / G2 hybrids.

[0398] By “Fc” or “Fc region” or “Fc domain” as used herein is meant the polypeptide comprising the constant region of an antibody, in some instances, excluding all of the first constant region immunoglobulin domain (e.g., CHI) or a portion thereof, and in some cases, optionally including all or part of the hinge. For IgG, the Fc domain comprises immunoglobulin domains CH2 and CH3 (Cy2 and Cy3), and optionally all or a portion of the hinge region between CHI (Cyl) and CH2 (Cy2). Thus, in some cases, the Fc domain includes, from N- to C- terminal, CH2-CH3 and hinge-CH2-CH3. In some embodiments, the Fc domain is that from IgGl, IgG2, or IgG4, with IgGl hinge-CH2-CH3 and IgG4 hinge-CH2-CH3 finding particular use in many embodiments. Additionally, in the case of human IgGl Fc domains, the hinge may include a C220S amino acid substitution. Furthermore, in the case of human IgG4 Fc domains, the hinge may include a S228P amino acid substitution. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to include residues E216, C226, or A231 to its carboxyl- terminal, wherein the numbering is according to the EU index as in Kabat. In some embodiments, as is more fully described below, amino acid modifications are made to the Fc region, for example to alter binding to one or more FcyR or to the FcRn.

[0399] By “heavy chain constant region” herein is meant the CHl-hinge-CH2-CH3 portion of an antibody (or fragments thereof), excluding the variable heavy domain; in EU numbering of human IgGl this is amino acids 118-447. By “heavy chain constant region fragment” herein is meant a heavy chain constant region that contains fewer amino acids from either or both of the N- and C-termini but still retains the ability to form a dimer with another heavy chain constant region.

[0400] Another type of domain of the heavy chain is the hinge region. By “hinge” or “hinge region” or “antibody hinge region” or “hinge domain” herein is meant the flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody. Structurally, the IgG CHI domain ends at EU position 215, and the IgG CH2 domain begins at residue EU position 231. Thus, for IgG the antibody hinge is herein defined to include positions 216 (E216 in IgGl) to 230 (P230 in IgGl), wherein the numbering is according to the EU index as in Kabat. In some cases, a “hinge fragment” is used, which contains fewer amino acids at either or both of the N- and C-termini of the hinge domain. As noted herein, pl variants can bemade in the hinge region as well. Many of the antibodies herein have at least one the cysteines at position 220 according to EU numbering (hinge region) replaced by a serine. Generally, this modification is on the “scFv monomer” side (when 1 + 1 or 2 + 1 formats are used) for most of the sequences depicted herein, although it can also be on the “Fab monomer” side, or both, to reduce disulfide formation. Specifically included within the sequences herein are one or both of these cysteines replaced (C220S).

[0401] As will be appreciated by those in the art, the exact numbering and placement of the heavy chain constant region domains (i.e., CHI, hinge, CH2 and CH3 domains) can be different among different numbering systems. A useful comparison of heavy constant region numbering according to EU and Kabat is as below, see Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85 and Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, entirely incorporated by reference.Table 1

[0402] The antibody light chain generally comprises two domains: the variable light domain (VL), which includes light chain CDRs vlCDRl-3, and a constant light chain region (often referred to as CL or CK). The antibody light chain is typically organized from N- to C-terminus: VL-CL.

[0403] By “antigen binding domain” or “ABD” herein is meant a set of six Complementary Determining Regions (CDRs) that, when present as part of a polypeptide sequence, specifically binds a target antigen (e.g., NKp46 or MICA / B) as discussed herein. As is known in the art, these CDRs are generally present as a first set of variable heavy CDRs (vhCDRs or VHCDRs) and a second set of variable light CDRs (vlCDRs or VLCDRs), each comprising three CDRs: vhCDRl, vhCDR2, vhCDR3 variable heavy CDRs and vlCDRl, vlCDR2 and vlCDR3 vhCDR3 variable light CDRs. The CDRs are present in the variable heavy domain (vhCDRl-3) andvariable light domain (vlCDRl-3). The variable heavy domain and variable light domain form an Fv region.

[0404] The present invention provides a large number of different CDR sets. In this case, a “full CDR set” comprises the three variable light and three variable heavy CDRs, e.g., a vlCDRl, vlCDR2, vlCDR3, vhCDRl, vhCDR2 and vhCDR3. These can be part of a larger variable light or variable heavy domain, respectfully. In addition, as more fully outlined herein, the variable heavy and variable light domains can be on separate polypeptide chains, when a heavy and light chain is used (for example when Fabs are used), or on a single polypeptide chain in the case of scFv sequences.

[0405] As will be appreciated by those in the art, the exact numbering and placement of the CDRs can be different among different numbering systems. However, it should be understood that the disclosure of a variable heavy and / or variable light sequence includes the disclosure of the associated (inherent) CDRs. Accordingly, the disclosure of each variable heavy region is a disclosure of the vhCDRs (e.g., vhCDRl, vhCDR2, and vhCDR3 (sometimes referred to collectively as vhCDRl-3)) and the disclosure of each variable light region is a disclosure of the vlCDRs (e.g., vlCDRl, vlCDR2, and vlCDR3 (sometimes referred to collectively as vlCDRl - 3)). A useful comparison of CDR numbering is as below, see Lafranc et al., Dev. Comp. Immunol. 27(1): 55-77 (2003).Table 2

[0406] Throughout the present specification, the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g., Kabat et al., supra (1991)).

[0407] The CDRs contribute to the formation of the antigen-binding, or more specifically, epitope binding site of the antigen binding domains and antibodies. “Epitope” refers to a determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. Epitopes are groupings of molecules such as amino acids or sugar side chains and usually have specific structural characteristics, as well as specific charge characteristics. A single antigen may have more than one epitope.

[0408] The epitope may comprise amino acid residues directly involved in the binding (also called immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked by the specifically antigen binding peptide; in other words, the amino acid residue is within the footprint of the specifically antigen binding peptide.

[0409] Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain.Conformational and non-conformational epitopes may be distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0410] An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Antibodies that recognize the same epitope can be verified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen, for example “binning.” As outlined below, the invention not only includes the enumerated antigen binding domains and antibodies herein, but those that compete for binding with the epitopes bound by the enumerated antigen binding domains.

[0411] In some embodiments, the six CDRs of the antigen binding domain are contributed by a variable heavy and a variable light domain. In a “Fab” format, the set of 6 CDRs are contributed by two different polypeptide sequences, the variable heavy domain (vh, VH, or VH; containing the vhCDRl, vhCDR2 and vhCDR3) and the variable light domain (vl, VL, or VL; containing the vlCDRl, vlCDR2 and vlCDR3), with the C-terminus of the vh domain being attached to the N-terminus of the CHI domain of the heavy chain and the C-terminus of the vl domain being attached to the N-terminus of the constant light domain (and thus forming the light chain). In a scFv format, the vh and vl domains are covalently attached, generally through the use of a linker(a “scFv linker”) as outlined herein, into a single polypeptide sequence, which can be either (starting from the N-terminus) vh-linker-vl or vl-linker-vh, with the former being generally preferred (including optional domain linkers on each side, depending on the format used. In general, the C-terminus of the scFv domain is attached to the N-terminus of all or part of the hinge in the second monomer.

[0412] By “variable region” or “variable domain” as used herein is meant the region of an immunoglobulin that comprises one or more Ig domains substantially encoded by any of the VK, V , and / or VH genes that make up the kappa, lambda, and heavy chain immunoglobulin genetic loci respectively, and contains the CDRs that confer antigen specificity. Thus, a “variable heavy domain” pairs with a “variable light domain” to form an antigen binding domain (“ABD”). In addition, each variable domain comprises three hypervariable regions (“complementary determining regions,” “CDRs”) (vhCDRl, vhCDR2 and vhCDR3 for the variable heavy domain and vlCDRl, vlCDR2 and vlCDR3 for the variable light domain) and four framework (FR) regions, arranged from amino-terminus to carboxy -terminus in the following order: FR1-CDR1- FR2-CDR2-FR3 -CDR3 -FR4.

[0413] By “Fab” or “Fab region” as used herein is meant the antibody region that comprises the VH, CHI, VL, and CL immunoglobulin domains, generally on two different polypeptide chains (e.g., VH-CH1 on one chain and VL-CL on the other). Fab may refer to this region in isolation, or this region in the context of a bispecific antibody of the invention. In the context of a Fab, the Fab comprises an Fv region in addition to the CHI and CL domains.

[0414] By “Fv” or “Fv fragment” or “Fv region” as used herein is meant the antibody region that comprises the VL and VH domains. Fv regions can be formatted as both Fabs (as discussed above, generally two different polypeptides that also include the constant regions as outlined above) and single chain Fvs (scFvs), where the vl and vh domains are included in a single peptide, attached generally with a linker as discussed herein.

[0415] By “single chain Fv” or “scFv” herein is meant a variable heavy domain covalently attached to a variable light domain, generally using a scFv linker as discussed herein, to form a scFv or scFv domain. A scFv domain can be in either orientation from N- to C-terminus (vh- linker-vl or vl-linker-vh). In the sequences depicted in the sequence listing and in the figures, the order of the vh and vl domain is indicated in the name, e.g., H.X L.Y means N- to C-terminal isvh-linker-vl, and L.Y H.X is vl-linker-vh.

[0416] Some embodiments of the subject antibodies provided herein comprise at least one scFv domain, which, while not naturally occurring, generally includes a variable heavy domain and a variable light domain, linked together by a scFv linker. As outlined herein, while the scFv domain is generally from N- to C-terminus oriented as VH-SCFV linker-Vt, this can be reversed for any of the scFv domains (or those constructed using vh and vl sequences from Fabs), to VL- scFv linker-Vu, with optional linkers at one or both ends depending on the format.

[0417] By “modification” or “variant” herein is meant an amino acid substitution, insertion, and / or deletion in a polypeptide sequence or an alteration to a moiety chemically linked to a protein. For example, a modification may be an altered carbohydrate or PEG structure attached to a protein. By “amino acid modification” herein is meant an amino acid substitution, insertion, and / or deletion in a polypeptide sequence. For clarity, unless otherwise noted, the amino acid modification is always to an amino acid coded for by DNA, e.g., the 20 amino acids that have codons in DNA and RNA.

[0418] By “amino acid substitution” or “substitution” herein is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence with a different amino acid. In particular, in some embodiments, the substitution is to an amino acid that is not naturally occurring at the particular position, either not naturally occurring within the organism or in any organism. For example, the substitution E272Y refers to a variant polypeptide, in this case an Fc variant, in which the glutamic acid at position 272 is replaced with tyrosine. For clarity, a protein which has been engineered to change the nucleic acid coding sequence but not change the starting amino acid (for example exchanging CGG (encoding arginine) to CGA (still encoding arginine) to increase host organism expression levels) is not an “amino acid substitution;” that is, despite the creation of a new gene encoding the same protein, if the protein has the same amino acid at the particular position that it started with, it is not an amino acid substitution.

[0419] By “amino acid insertion” or “insertion” as used herein is meant the addition of an amino acid sequence at a particular position in a parent polypeptide sequence. For example, -233E or 233E designates an insertion of glutamic acid after position 233 and before position 234. Additionally, -233ADE or A233ADE designates an insertion of AlaAspGlu after position 233 and before position 234.

[0420] By “amino acid deletion” or “deletion” as used herein is meant the removal of an amino acid sequence at a particular position in a parent polypeptide sequence. For example, E233- or E233#, E233(), E233_ or E233del designates a deletion of glutamic acid at position 233. Additionally, EDA233- or EDA233# designates a deletion of the sequence GluAspAla that begins at position 233.

[0421] By “variant protein” or “protein variant,” or “variant” as used herein is meant a protein that differs from that of a parent protein by virtue of at least one amino acid modification. The protein variant has at least one amino acid modification compared to the parent protein, yet not so many that the variant protein will not align with the parental protein using an alignment program such as that described below. In general, variant proteins (such as variant Fc domains, etc., outlined herein, are generally at least 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to the parent protein, using the alignment programs described below, such as BLAST.

[0422] ‘ ‘Variant” as used herein also refers to particular amino acid modifications that confer particular function (e.g., a “heterodimerization variant,” “pl variant,” “ablation variant,” etc.).

[0423] As described below, in some embodiments the parent polypeptide, for example an Fc parent polypeptide, is a human wild-type sequence, such as the heavy constant domain or Fc region from IgGl, IgG2, or IgG4, although human sequences with variants can also serve as “parent polypeptides,” for example the IgGl / 2 hybrid of US Publication 2006 / 0134105 can be included. The protein variant sequence herein will preferably possess at least about 80% identity with a parent protein sequence, and most preferably at least about 90% identity, more preferably at least about 95-98-99% identity. Accordingly, by “antibody variant” or “variant antibody” as used herein is meant an antibody that differs from a parent antibody by virtue of at least one amino acid modification, “IgG variant” or “variant IgG” as used herein is meant an antibody that differs from a parent IgG (again, in many cases, from a human IgG sequence) by virtue of at least one amino acid modification, and “immunoglobulin variant” or “variant immunoglobulin” as used herein is meant an immunoglobulin sequence that differs from that of a parent immunoglobulin sequence by virtue of at least one amino acid modification. “Fc variant” or “variant Fc” as used herein is meant a protein comprising an amino acid modification in an Fc domain as compared to an Fc domain of human IgGl, IgG2 or IgG4.

[0424] “Fc variant” or “variant Fc” as used herein is meant a protein comprising an amino acidmodification in an Fc domain. The modification can be an addition, deletion, or substitution. The Fc variants are defined according to the amino acid modifications that compose them. Thus, for example, N434S or 434S is an Fc variant with the substitution for serine at position 434 relative to the parent Fc polypeptide, wherein the numbering is according to the EU index. Likewise, M428L / N434S defines an Fc variant with the substitutions M428L and N434S relative to the parent Fc polypeptide. The identity of the WT amino acid may be unspecified, in which case the aforementioned variant is referred to as 428L / 434S. It is noted that the order in which substitutions are provided is arbitrary, that is to say that, for example, 428L / 434S is the same Fc variant as 434S / 428L, and so on. For all positions discussed herein that relate to antibodies or derivatives and fragments thereof (e.g., Fc domains), unless otherwise noted, amino acid position numbering is according to the EU index. The “EU index” or “EU index as in Kabat’ ’ or “EU numbering” scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, hereby entirely incorporated by reference). The modification can be an addition, deletion, or substitution.

[0425] In general, variant Fc domains have at least about 80, 85, 90, 95, 96, 97, 98 or 99 percent identity to the corresponding parental human IgG Fc domain (using the identity algorithms discussed below, with one embodiment utilizing the BLAST algorithm as is known in the art, using default parameters). Alternatively, the variant Fc domains can have from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications as compared to the parental Fc domain. Alternatively, the variant Fc domains can have up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications as compared to the parental Fc domain. Additionally, as discussed herein, the variant Fc domains described herein still retain the ability to form a dimer with another Fc domain as measured using known techniques as described herein, such as non-denaturing gel electrophoresis.

[0426] By “protein” as used herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides, and peptides. In addition, polypeptides that make up the antibodies of the invention may include synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, linkers to other molecules, fusion to proteins or protein domains, and addition of peptide tags or labels.

[0427] By “residue” as used herein is meant a position in a protein and its associated amino acid identity. For example, Asparagine 297 (also referred to as Asn297 or N297) is a residue at position 297 in the human antibody IgGl.

[0428] By “IgG subclass modification” or “isotype modification” as used herein is meant an amino acid modification that converts one amino acid of one IgG isotype to the corresponding amino acid in a different, aligned IgG isotype. For example, because IgGl comprises a tyrosine and IgG2 a phenylalanine at EU position 296, a F296Y substitution in IgG2 is considered an IgG subclass modification.

[0429] By “non-naturally occurring modification” as used herein is meant an amino acid modification that is not isotypic. For example, because none of the human IgGs comprise a serine at position 434, the substitution 434S in IgG...

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A MICA / B antigen binding domain comprising a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837_1E11_1 [MICA / B ]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B] H2 D94837 1E11 1 [MICA / B] LI, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B] HO D94852 2E12 [MICA / B] LO, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B] _L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD103388JC7 [MICA / B]_H2_D1O 388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H0_D103388_lD7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICAZB]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD99136 2C11 [MICA / B] Hl D99136 2C 11 [MICA / B] LI, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1B11-2 [MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852 2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487 2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12[MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, and (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487 2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, as depicted in Figure 21.

2. A MICA / B antigen binding domain comprising a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E1 I I [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] Hl 2E5 [MICA / B] LI, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H2_2E5 [MICA / B]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX andXXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] HO D103388 1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1 , (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H I D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for DI 05317 J A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBll-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for DI 05317_1F7 [MICA / B]_HO_D1O5317 1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX forD94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837 3B12 [MICA / B] HO D94837 3B12 [MICA / B] LO, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, and (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, as depicted in Figure 21.

3. An antibody comprising a MICA / B antigen binding domain according to claim 1 or 2.

4. The antibody according to claim 3, wherein the antibody is a monoclonal antibody.

5. The antibody according to claim 3, wherein the antibody is a bispecific antibody.

6. A composition comprising a MICA / B antigen binding domain according to claim 1 or 2 or an antibody according to any one of claims 3-5.

7. A nucleic acid composition comprising (a) a first nucleic acid encoding the variable heavy domain according to any one of claims 1-5; and (b) a second nucleic acid encoding the variable light domain according to any one of claims 1-5.

8. An expression vector composition comprising (a) a first expression vector comprising the first nucleic acid according to claim 7; and (b) a second expression vector comprising the second nucleic acid composition according to claim 7.

9. A host cell comprising the expression vector composition according to claim 8.

10. A method of making a MICA / B antigen binding domain or an antibody comprising such, the method comprising culturing a host cell according to claim 9 under conditions wherein the MICA / B antigen binding domain or the antibody comprising such is expressed, and recovering the MICA / B antigen binding domain or the antibody comprising such.

11. A NKp46 antigen binding domain comprising a set of vhCDRl-3 and vlCDRl-3 from avariable heavy domain and variable light domain pair selected from the group consisting of: SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, as depicted in Figure 23.

12. A NKp46 antigen binding domain comprising a variable heavy domain and variable light domain pair selected from the group consisting of: SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, as depicted in Figure 23.

13. An antibody comprising a NKp46 antigen binding domain according to claim 11 or 12.

14. The antibody according to claim 13, wherein the antibody is a monoclonal antibody.

15. The antibody according to claim 13, wherein the antibody is a bispecific antibody.

16. A composition comprising a NKp46 antigen binding domain according to claim 11 or 12 or an antibody according to any one of claims 13-15.

17. A nucleic acid composition comprising (a) a first nucleic acid encoding the variable heavy domain according to any one of claims 11-15; and (b) a second nucleic acid encoding the variable light domain according to any one of claims 11-15.

18. An expression vector composition comprising (a) a first expression vector comprising the first nucleic acid according to claim 17; and (b) a second expression vector comprising the second nucleic acid composition according to claim 17.

19. A host cell comprising the expression vector composition according to claim 18.

20. A method of making a NKp46 antigen binding domain or an antibody comprising such, the method comprising culturing a host cell according to claim 19 under conditions wherein the MICA / B antigen binding domain or the antibody comprising such is expressed, and recovering the MICA / B antigen binding domain or the antibody comprising such.

21. A heterodimeric antibody, comprising:(a) a first monomer, comprising:(i) an anti-NKp46 scFv comprising a first variable heavy VH1 domain, an scFv linker, and a first variable light VL1 domain; and(ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;(b) a second monomer comprising a VH2-CHl-hinge-CH2-CH3 monomer, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain; and(c) a light chain comprising a second variable light VL2 domain, wherein the second variable heavy VH2 domain and the second variable light VL2 domain form a MICA / B antigen binding domain.

22. The heterodimeric antibody according to claim 21, wherein the MICA / B antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837_1E11_1 [MICA / B]_HO_D94837_1E1 I I [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ IDNOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B] LI, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H0_D103388_lD7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICAZB]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B] HO D 105317 1A2 [MICA / B] L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317 1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8[MICA / B] HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

23. The heterodimeric antibody according to claim 21 or 22, wherein the MICA / B antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos:XXX and XXX for D94837_1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] Hl 2E5 [MICA / B] L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D991 6 2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1,(xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICAZB]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B] HO D99136 2C11 [MICA / B] LO, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICAZB]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5[MICA / B]_HO_1D5 [MICA / B]_LO, as depicted in Figures 21 and 22.

24. The heterodimeric antibody according to any one of claims 21-23, wherein the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and first variable light VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

25. The heterodimeric antibody according to any one of claims 21-24, wherein the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

26. The heterodimeric antibody according to any one of claims 21-25, wherein the first variable light VL1 domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

27. The heterodimeric antibody according to any one of claims 21-25, wherein the first variable heavy VH1 domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

28. The heterodimeric antibody according to any one of claims 21-27 selected from the group consisting of: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP46810, (ii) the amino acid sequences of SEQ ID NOS: XXX-XXX of XENP46811, and (iii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP46812, as depicted in Figure 31.

29. A heterodimeric antibody, comprising:(a) a first monomer, comprising:(i) an anti-MICA / B scFv comprising a first variable heavy VH1 domain, an scFvlinker, and a first variable light VL1 domain; and(ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;(b) a second monomer comprising a VH2-CHl-hinge-CH2-CH3 monomer, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain; and(c) a light chain comprising a second variable light VL2 domain, wherein the second variable heavy VH2 domain and the second variable light VL2 domain form a NKp46 antigen binding domain.

30. The heterodimeric antibody according to claim 29, wherein the NKp46 antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46- A[NKp46]_H_ NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.31 . The heterodimeric antibody according to claim 29 or 30, wherein the NKp46 antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

32. The heterodimeric antibody according to any one of claims 29-31, wherein the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl -3 from a first variable heavy VH1 domain and first variable light VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICAZB]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_HO_D1O3388_1C7[MICA / B]_LO, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B] H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B] H2 DI 03388 1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MIC A / B]_H2_D 10 388 J D7 [MIC A / B]_L 1 , (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H0_D 105317 1 A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_Hl_D105317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [M1CA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B] L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317 1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837JD9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

33. The heterodimeric antibody according to any one of claims 29-32, wherein the anti -MIC A / B scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MIC A / B] Hl 2E5 [MIC A / B] LI, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID Nos: XXX andXXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] HO D103388 1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1 , (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H I D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for DI 05317 J A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBll-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for DI 05317_1F7 [MICA / B]_HO_D1O5317 1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX forD94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837 3B12 [MICA / B] HO D94837 3B12 [MICA / B] L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

34. The heterodimeric antibody according to any one of claims 29-33, wherein the first variable light VL1 domain of the anti -MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

35. The heterodimeric antibody according to any one of claims 29-33, wherein the first variable heavy VH1 domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

36. The heterodimeric antibody according to any one of claims 21-35, wherein the scFv linker is a charged scFv linker.

37. The heterodimeric antibody according to claim 36, wherein the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

38. The heterodimeric antibody according to any one of claims 21-37, wherein the first and second Fc domains are each variant Fc domains.

39. The heterodimeric antibody according to claim 38, wherein the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

40. The heterodimeric antibody according to claim 39, wherein the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group consisting of: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

41. The heterodimeric antibody according to claim 39 or 40, wherein the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group consisting of: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

42. The heterodimeric antibody according to any one of claims 39-41, wherein the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

43. The heterodimeric antibody according to any one of claims 38-42, wherein the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

44. The heterodimeric antibody according to claim 43, wherein the set of heterodimerization variants is selected from the group consisting of: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

45. The heterodimeric antibody according to any one of claims 38-44, wherein the first and second variant Fc domains further comprise one or more ablation variants.

46. The heterodimeric antibody according to claim 45, wherein the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

47. The heterodimeric antibody according to any one of claims 21-46, wherein one of the first or second variant Fc domain comprises one or more pl variants.

48. The heterodimeric antibody according to claim 47, wherein the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

49. The heterodimeric antibody according to any one of claims 21-48, wherein the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

50. The heterodimeric antibody according to any one of claims 21-49, wherein the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

51. A nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody according to any one of claims 21-50.

52. An expression vector comprising the nucleic acids according to claim 51.

53. A host cell transformed with an expression vector according to claim 52.

54. A method of making a heterodimeric antibody comprising:(a) culturing the host cell according to claim 53 under conditions wherein the heterodimeric antibody is expressed; and(b) recovering the heterodimeric antibody.

55. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -[first optional domain linker] -scFv- [second optional domain linker]-CH2-CH3, wherein VH1 is a first variable heavy VH1 domain, scFv is an anti-MICA / B scFv, and CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a CH2-CH3, wherein the CH2-CH3 is a second Fc domain; and(c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light VH1 domain and CL is a constant light domain, wherein: (i) the first variable heavy VH1 domain and the first variable light VL1 domain form a NKp46 antigen binding domain, (ii) the anti-MICA / B scFv comprises a second variable heavy VH2 domain, a scFv linker, and a second variable light VL2 domain, and (iii) the anti-MICA / B scFv is covalently attached between the C-terminus of the CHI domain and the N-terminus of the first Fc domain.

56. The heterodimeric antibody according to claim 55, wherein the NKp46 antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

57. The heterodimeric antibody according to claim 55 or 56, wherein the NKp46 antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for2C10A3.372[NKp46] Hl 2C10A3.372[NKp46] LI, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

58. The heterodimeric antibody according to any one of claims 55-57, wherein the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl -3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E1 1 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl -3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICAZB]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_HO_D1O3388_1C7[MICA / B]_LO, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B] H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B] H2 DI 03388 1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MIC A / B]_H2_D 10 388 J D7 [MIC A / B]_L 1 , (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H0_D 105317 1 A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_Hl_D105317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B] L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317 1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837JD9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

59. The heterodimeric antibody according to any one of claims 55-58, wherein the anti-MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] Hl 2E5 [MICA / B] LI, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX andXXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] HO D103388 1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1 , (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H I D 105317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for DI 05317 J A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBll-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for DI 05317_1F7 [MICA / B]_HO_D1O5317 1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX forD94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_LO, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837 3B12 [MICA / B] HO D94837 3B12 [MICA / B] LO, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

60. The heterodimeric antibody according to any one of claims 55-59, wherein:(i) the anti-MICA / B scFv comprises, from N-terminus to C-terminus, VH2-scFv linker- VL2;(ii) the variable heavy domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker; and(iii) the variable light domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker.

61. The heterodimeric antibody according to any one of claims 55-59, wherein:(i) the anti-MICA / B scFv comprises, from N-terminus to C-terminus, VL2-scFv linker- VH2;(ii) the variable light domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker; and(iii) the variable heavy domain is covalently attached to the N-terminus of the first Fcdomain, optionally using a second domain linker.

62. The heterodimeric antibody according to any one of claims 55-61 selected from the group consisting of: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47274, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47281, as depicted in Figure 32.

63. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -[first optional domain linker] -scFv- [second optional domain linker]-CH2-CH3, wherein VH1 is a first variable heavy VH1 domain, scFv is an anti-NKp46 scFv, and CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a CH2-CH3, wherein the CH2-CH3 is a second Fc domain; and(c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light VH1 domain and CL is a constant light domain, wherein: (i) the first variable heavy VH1 domain and the first variable light VL1 domain form a MICA / B antigen binding domain, (ii) the anti-NKp46 scFv comprises a second variable heavy VH2 domain, a scFv linker, and a second variable light VL2 domain, and (iii) the anti-NKp46 scFv is covalently attached between the C-terminus of the CHI domain and the N-terminus of the first Fc domain.

64. The heterodimeric antibody according to claim 63, wherein the MICA / B antigen binding domain comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L 1 , (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B] HO 2E5 [MICA / B] LO, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICAZB]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388JC7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICAZB]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD103388 1C7 [MICA / B] H2 D103388 1C7 [MICA / B] L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICAZB]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2[MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NO s: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1D3 [MICA / B]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837JEl [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICAZB]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICAZB] H0 D94837 3B12 [MICA / B]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9[MICA / B] H0_13A9 [MICA / B]_LO, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

65. The heterodimeric antibody according to claim 63 or 64, wherein the MICA / B antigen binding domain comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] H2 2E5 [MICA / B] LI, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ IDNos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7[MICA / B] Hl D103388 1D7 [MICA / B] LI, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for DI 05317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B ]_HO_D105317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX forD94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_LO, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B] HO D99136 2E8 [MICA / B] _L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

66. The heterodimeric antibody according to any one of claims 63-65, wherein the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

67. The heterodimeric antibody according to any one of claims 63-66, wherein the anti-NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for2C10A3.372[NKp46] Hl 2C10A3.372[NKp46] LI, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

68. The heterodimeric antibody according to any one of claims 63-67, wherein:(i) the anti-NKp46 scFv comprises, from N-terminus to C-terminus, VH2-scFv linker- VL2;(ii) the variable heavy domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker; and(iii) the variable light domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker.

69. The heterodimeric antibody according to any one of claims 63-67, wherein:(i) the anti-NKp46 scFv comprises, from N-terminus to C-terminus, VL2-scFv linker- VH2;(ii) the variable light domain is covalently attached to the C-terminus of the CHI domain, optionally using a first domain linker; and(iii) the variable heavy domain is covalently attached to the N-terminus of the first Fc domain, optionally using a second domain linker.

70. The heterodimeric antibody according to any one of claims 55-69, wherein the scFv linker is a charged scFv linker.

71. The heterodimeric antibody according to claim 70, wherein the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ LD NO: XXX).

72. The heterodimeric antibody according to any one of claims 55-71, wherein the first and second Fc domains are each variant Fc domains.

73. The heterodimeric antibody according to claim 72, wherein the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

74. The heterodimeric antibody according to claim 73, wherein the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group consisting of: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

75. The heterodimeric antibody according to claim 73 or 74, wherein the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group consisting of: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E,(iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

76. The heterodimeric antibody according to any one of claims 73-75, wherein the first and / or second variant Fc domains comprise the FcyRIIIA (CD16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

77. The heterodimeric antibody according to any one of claims 72-76, wherein the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

78. The heterodimeric antibody according to claim 77, wherein the set of heterodimerization variants is selected from the group consisting of (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

79. The heterodimeric antibody according to any one of claims 72-78, wherein the first and second variant Fc domains further comprise one or more ablation variants.

80. The heterodimeric antibody according to claim 79, wherein the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

81. The heterodimeric antibody according to any one of claims 55-80, wherein one of the first or second variant Fc domain comprises one or more pl variants.

82. The heterodimeric antibody according to claim 81, wherein the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

83. The heterodimeric antibody according to any one of claims 55-82, wherein the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421 D / E233P / L234 V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

84. The heterodimeric antibody according to any one of claims 55-83, wherein the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

85. A nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody according to any one of claims 55-84.

86. An expression vector comprising the nucleic acids according to claim 85.

87. A host cell transformed with an expression vector according to claim 86.

88. A method of making a heterodimeric antibody comprising:(a) culturing the host cell according to claim 87 under conditions wherein the heterodimeric antibody is expressed; and(b) recovering the heterodimeric antibody.

89. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -first linker- scFv-second linker-CH2-CH3, wherein the VH1 is a first variable heavy domain, the scFv is an anti-NKp46 scFv, and the CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge- CH2-CH3, wherein the VH2 is a second variable heavy domain and the CH2-CH3 is a second Fc domain; and(c) a common light chain comprising, from N-terminus to C-terminus, a VL-CL, wherein the VL is a variable light domain, and the CL is a light chain constant domain, wherein the first variable heavy VH1 domain and the variable light VL domain form a first MICA / B antigen binding domain, and the second variably heavy VH2 domain andthe variable light VL domain form a second MICA / B antigen binding domain.

90. The heterodimeric antibody according to claim 89, wherein the first and / or second MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B] HO 2E5 [MICA / B] L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B] _L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD103388JC7 [MICA / B]_H2_D1O 388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B ]_L1, (xxxv) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICAZB]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD99136 2C11 [MICA / B] Hl D99136 2C 11 [MICA / B] LI, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1B11-2 [MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852 2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487 2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12[MICA / B] H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487 2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of6E1 [MICA / B ]_HO_6E1 [MIC A / B]_L0, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

91. The heterodimeric antibody according to claim 89 or 90, wherein the first and / or second MICA / B antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11_1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXXand XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B] Hl D99136 2F7 [MICA / B] L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388JD7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBl l-2 [MICA / B]_LO, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317JC8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D1O5317_1F6 [MICA / B]_HO_D1O5317_1F6 [MICA / B]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317 1F7 [MICA / B] HO DI 05317 1F7 [MICA / B] LO, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

92. The heterodimeric antibody according to any one of claims 89-91, wherein the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and a first variable light VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

93. The heterodimeric antibody according to any one of claims 89-92, wherein the anti-NKp46scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

94. The heterodimeric antibody according to any one of claims 89-93, wherein the variable light domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

95. The heterodimeric antibody according to any one of claims 89-93, wherein the variable heavy domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

96. The heterodimeric antibody according to any one of claims 89-95 selected from the group consisting of: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47438, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47439, as depicted in Figure 33.

97. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -first linker- scFv-second linker-CH2-CH3, wherein the VH1 is a first variable heavy domain, the scFv is an anti-MICA / B scFv, and the CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge- CH2-CH3, wherein the VH2 is a second variable heavy domain and the CH2-CH3 is a second Fc domain; and(c) a common light chain comprising, from N-terminus to C-terminus, a VL-CL, wherein the VL is a variable light domain, and the CL is a light chain constant domain, wherein the first variable heavy VH1 domain and the variable light VL domain form a first NKp46 antigen binding domain, and the second variably heavy VH2 domain and the variable light VL domain form a second NKp46 antigen binding domain.

98. The heterodimeric antibody according to claim 97, wherein the first and / or second NKp46antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46] H NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

99. The heterodimeric antibody according to claim 97 or 98, wherein the first and / or second NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

100. The heterodimeric antibody according to any one of claims 97-99, wherein the anti- MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy VH1 domain and a first variable light VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837_1E11_1 [MICA / B ]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B] H2 D94837 1E11 1 [MICA / B] LI, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ IDNOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B] LI, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICAZB]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD105317 1A2 [MICA / B] HO D 105317 1A2 [MICA / B] LO, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D 103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of DI 05317 1 C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317 1F6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8[MICAZB] H0 D94837 1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2D4 [MICA / B]_H0_D948 2_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

101. The heterodimeric antibody according to any one of claims 97-100, wherein the anti- MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos:XXX and XXX for D94837_1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] Hl 2E5 [MICA / B] L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D991 6 2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1,(xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICAZB]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B] HO D99136 2C11 [MICA / B] LO, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICAZB]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5[MICA / B] HO_1D5 [MICA / B]_LO, as depicted in Figures 21 and 22.

102. The heterodimeric antibody according to any one of claims 97-101, wherein the variable light domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

103. The heterodimeric antibody according to any one of claims 97-101, wherein the variable heavy domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

104. The heterodimeric antibody according to any one of claims 89-103, wherein the scFv linker is a charged scFv linker.

105. The heterodimeric antibody according to claim 104, wherein the scFv linker is a charged linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

106. The heterodimeric antibody according to any one of claims 89-105, wherein the first and second Fc domains are each variant Fc domains.

107. The heterodimeric antibody according to claim 106, wherein the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

108. The heterodimeric antibody according to claim 107, wherein the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group consisting of: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

109. The heterodimeric antibody according to claim 107 or 108, wherein the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group consisting of: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E :S239D, wherein numbering is according to EU numbering.

110. The heterodimeric antibody according to any one of claims 106-109, wherein the first and / or second variant Fc domains comprise the FcyRIIIA (CD 16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

111. The heterodimeric antibody according to any one of claims 106-110, wherein the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

112. The heterodimeric antibody according to claim 111, wherein the set of heterodimerization variants is selected from the group consisting of: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T41 1E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

113. The heterodimeric antibody according to any one of claims 106-112, wherein the first and second variant Fc domains further comprise one or more ablation variants.

114. The heterodimeric antibody according to claim 113, wherein the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

115. The heterodimeric antibody according to any one of 89-114, wherein one of the first or second variant Fc domain comprises one or more pl variants.

116. The heterodimeric antibody according to claim 115, wherein the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

117. The heterodimeric antibody according to any one of claims 89-116, wherein the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.

118. The heterodimeric antibody according to any one of claims 89-117, wherein the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

119. A nucleic acid composition comprising nucleic acids encoding the first and second monomers and the common light chain of the antibody according to any one of claims 89-118.

120. An expression vector comprising the nucleic acids according to claim 119.

121. A host cell transformed with an expression vector according to claim 120.

122. A method of making a heterodimeric antibody comprising:(a) culturing the host cell according to claim 121 under conditions wherein the heterodimeric antibody is expressed; and(b) recovering the heterodimeric antibody.

123. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -hinge-first linker- VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain;(b) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, and wherein the VH1 and VL1 form MICA / B antigen binding domains; and(c) a second monomer comprising, from N-terminus to C-terminus, an anti-NKp46 scFv and a second Fc domain, wherein the scFv is covalently attached to the N-terminus of the second Fc domain using a domain linker.

124. The heterodimeric antibody according to claim 123, wherein the anti-NKp46 scFv comprises a second variable heavy VH2 domain, an scFv linker, and a second variable light VL2 domain.

125. The heterodimeric antibody according to claim 123 or 124, wherein the anti-NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46] Hl 2C10A3.372[NKp46] LI, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

126. The heterodimeric antibody according to any one of claims 123-125, wherein the anti- NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

127. The heterodimeric antibody according to any one of claims 123-126, wherein each of the MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair, wherein the set of vhCDRl-3 and vlCDRl-3 is selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837JE11 1 [MICA / B ]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX- XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5[MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852 2E12 [MICA / B] Hl D94852 2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_HI_D103388_ID7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXXforvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B] _L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H0_D 105317 1 A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_Hl_D105317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2CH [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICAZB]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1E1 [MICA / B] HO D94837 1E1 [MICA / B] LO, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICAZB]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICAZB]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

128. The heterodimeric antibody according to any one of claims 123-127, wherein each of the MICA / B antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX andXXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] Hl 2E5 [MICA / B] LI, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388JC7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317 1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii)SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317 1A2 [MICA / B] H2 D105317 1A2 [MICA / B] L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBll-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317JC8 [MICA / B]_HO_D1O5 17_1C8 [MICA / B]_L0, (xliv) SEQ ID Nos: XXX and XXX for D1O5317_1F6 [MICA / B ]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for DI 05317_1F7 [MICA / B]_HO_D1O5317 1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837 1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B 12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[M1CA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9[MICA / B]_H0_13A9 [MICA / B]_LO, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

129. The heterodimeric antibody according to any one of claims 123-128 selected from the group consisting of: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47442, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47443, as depicted in Figure 34.

130. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VH1 -CHI -hinge-first linker- VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain;(b) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, and wherein the VH1 and VL1 form NKp46 antigen binding domains; and(c) a second monomer comprising, from N-terminus to C-terminus, an anti-MICA / B scFv and a second Fc domain, wherein the scFv is covalently attached to the N-terminus of the second Fc domain using a second linker.131 . The heterodimeric antibody according to claim 130, wherein the anti-MICA / B scFv comprises a second variable heavy VH2 domain, an scFv linker, and a second variable light VL2 domain.

132. The heterodimeric antibody according to claim 130 or 131, wherein the anti-MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1[MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11_1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B] HO 2E5 [MICA / B] LO, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ IDNOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICAZB]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD103388 1C7 [MICA / B] H2 D103388 1C7 [MICA / B] L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B ]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D1O5317_1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B ]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B ]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICA / B]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2[MIC A / B]_HO_D103388 1B 11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NO s: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D1O5317_1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1D3 [MICA / B]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837JEl [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICAZB]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICAZB] H0 D94837 3B12 [MICA / B]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9[MICA / B] H0_13A9 [MICA / B]_LO, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

133. The heterodimeric antibody according to any one of claims 130-132, wherein the anti- MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B] H2 2E5 [MICA / B] LI, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ IDNos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_HO_D1O3388_1D7 [MICAZB]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B] Hl D103388 1D7 [MICA / B] LI, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for DI 05317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_H0_D103388_lBl 1-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B ]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B ]_HO_D105317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317 1F7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX forD94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_LO, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B] HO D99136 2E8 [MICA / B] _L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

134. The heterodimeric antibody according to any one of claims 130-133, wherein each of the NKp46 antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair, wherein the set of vhCDRl-3 and vlCDRl-3 is selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

135. The heterodimeric antibody according to any one of claims 130-134, wherein each of the NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46] Hl 2C10A3.372[NKp46] LI, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

136. The heterodimeric antibody according to any one of claims 123-135, wherein the scFv linker is a charged scFv linker.

137. The heterodimeric antibody according to claim 136, wherein the scFv linker is a charged scFv linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

138. The heterodimeric antibody according to any one of claims 123-137, wherein the first andsecond linkers are each domain linkers.

139. The heterodimeric antibody according to any one of claims 123-138, wherein the first and second Fc domains are each variants Fc domains.

140. The heterodimeric antibody according to claim 139, wherein the first and / or second variant Fc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

141. The heterodimeric antibody according to claim 140, wherein the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group consisting of: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

142. The heterodimeric antibody according to any one of claims 139-141, wherein the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group consisting of: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

143. The heterodimeric antibody according to any one of claims 139-142, wherein the first and / or second variant Fc domains comprise the FcyRIIIA (CD 16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

144. The heterodimeric antibody according to any one of claims 139-143, wherein the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

145. The heterodimeric antibody according to claim 144, wherein the set of heterodimerization variants is selected from the group consisting of: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W: T366S / L368A / Y407V, wherein numbering is according to EU numbering.

146. The heterodimeric antibody according to any one of claims 139-145, wherein the first and second Fc variant domains further comprise one or more ablation variants.

147. The heterodimeric antibody according to claim 146, wherein the one or more ablation variants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

148. The heterodimeric antibody according to any one of claims 123-147, wherein the first or second variant Fc domain further comprises one or more pl variants.

149. The heterodimeric antibody according to claim 148, wherein the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

150. The heterodimeric antibody according to any one of claims 123-149, wherein the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variants L368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235A / G236del / S267K, and wherein numbering is according to EU numbering.151 . The heterodimeric antibody according to any one of claims 123-150, wherein the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

152. A nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody according to any one of claims 123-151.

153. An expression vector comprising the nucleic acids according to claim 152.

154. A host cell transformed with an expression vector according to claim 153.

155. A method of making a heterodimeric antibody comprising:(a) culturing the host cell according to claim 154 under conditions wherein the heterodimeric antibody is expressed; and(b) recovering the heterodimeric antibody.

156. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-hinge-CH2- CH3-domain linker-scFv, wherein VH1 is a first variable heavy domain, scFv is an anti- NKp46 scFv, and CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge- CH2-CH3, wherein CH2-CH3 is a second Fc domain; and(c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, wherein the VH1 and the VL1 form a first MICA / B antigen binding domain, the VH2 domain and the VL1 form a second MICA / B antigen binding domain, and the anti-NKp46 scFv comprises a VH3 domain, a scFv linker, and a VL2 domain.

157. The heterodimeric antibody according to claim 156, wherein the first and / or second MICA / B antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837 1E11 1 [MICA / B] HO D94837 1E11 1 [MICA / B] LO, (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11 1 [MICA / B ]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B ]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICA / B]_H2_D94837_1E11 1 [MICA / B ]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5[MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICAZB]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of2E5 [MICA / B] H2 2E5 [MICA / B] L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B ]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B ]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136_2F7 [MICA / B]_HI_D99I36_2F7 [MICA / B ]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388JC7 [MICA / B ]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B ]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7[MICA / B]_HO_D1O3388_1D7 [MICA / B]_LO, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1A2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of DI 05317 1 A2 [MICA / B]_H2_D105317_l A2 [MICA / B]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D105317_IA2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICAZB]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C 11 [MICAZB]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICAZB]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICAZB]_HO_DIO3388_1B11-2 [MICA / B]_L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDR 1- 3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D105317 1B6 [MICA / B]_HO_D1O5317 1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of D105317 1C8 [MICA / B]_H0_D105317_lC8 [MICA / B]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICAZB]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1D8 [MICA / B] HO D94837 1D8 [MICA / B] LO, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICAZB]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD94837_lEl [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICAZB]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9 [MICA / B]_H0_13A9 [MICA / B ]_L0, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

158. The heterodimeric antibody according to claim 156 or 157, wherein the first and / or second MICA / B antigen binding domains comprise a variable heavy domain and variable light domainpair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837_1E11 1 [MICAZB]_HO_D94837_1E11 1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] H2 D94837 1E11 1 [MICA / B] LI, (v) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B ]_H2_D94837_1E1 I I [MICA / B]_L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICAZB]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B ]_L2, (xxi) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B ]_L0, (xxii) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D1O3388_1C7 [MICA / B ]_H2_D1O3388_1C7 [MICA / B ]_L1, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX andXXX for D103388 1D7 [MICA / B ]_H2_D1O3388_1D7 [MICA / B]_L1 , (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for DI 05317 _1A2 [MICA / B] Hl D105317 1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D105317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136 2C11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX forD103388 1B11-2 [MICA / B]_H0_D103388_lBll-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_H0_D105317_lB6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D105317 1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for DI 05317_1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D105317_1F7 [MICA / B]_HO_D1O5317 1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID Nos: XXX and XXX for D94837 1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837_1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852_2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICAZB]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B] HO 1D5 [MICA / B] LO, as depicted in Figures 21 and 22.

159. The heterodimeric antibody according to any one of claims 156-158, wherein the anti- NKp46 scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy chain VH1 domain and first variable light chain VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

160. The heterodimeric antibody according to any one of claims 156-159, wherein the anti- NKp46 scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

161. The heterodimeric antibody according to any one of claims 156-160, wherein the variable light domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

162. The heterodimeric antibody according to any one of claims 156-160, wherein the variable heavy domain of the anti-NKp46 scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

163. The heterodimeric antibody according to any one of claims 156-162 selected from the group consisting of: (i) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47446, and (ii) the amino acid sequences of SEQ ID NOs: XXX-XXX of XENP47447, as depicted in Figure 35.

164. A heterodimeric antibody, comprising:(a) a first monomer comprising, from N-terminus to C-terminus, a VHl-CHl-hinge-CH2- CH3-domain linker-scFv, wherein VH1 is a first variable heavy domain, scFv is an anti- MICA / B scFv, and CH2-CH3 is a first Fc domain;(b) a second monomer comprising, from N-terminus to C-terminus, a VH2-CHl-hinge- CH2-CH3, wherein CH2-CH3 is a second Fc domain; and(c) a light chain comprising, from N-terminus to C-terminus, a VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, wherein the VH1 and the VL1 form a first NKp46 antigen binding domain, the VH2 domain and the VL1 form a second NKp46 antigen binding domain, and the anti-NKp46 scFv comprises a VH3 domain, a scFv linker, and a VL2 domain.

165. The heterodimeric antibody according to claim 164, wherein the first and / or second NKp46 antigen binding domains comprise a set of vhCDRl-3 and vlCDRl-3 from a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of NKp46-A[NKp46]_H_NKp46- A[NKp46]_L, as depicted in Figures 23 and 24.

166. The heterodimeric antibody according to claim 164 or 165, wherein the first and / or second NKp46 antigen binding domains comprise a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for 2C10A3.372[NKp46]_Hl_2C10A3.372[NKp46]_Ll, and (ii) SEQ ID Nos: XXX and XXX for NKp46-A[NKp46]_H_ NKp46-A[NKp46]_L, as depicted in Figures 23 and 24.

167. The heterodimeric antibody according to any one of claims 164-166, wherein the anti- MICA / B scFv comprises a set of vhCDRl-3 and vlCDRl-3 from a first variable heavy chain VH1 domain and first variable light chain VL1 domain pair selected from the group consisting of: (i) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl -3 of D94837_1E11_1 [MICA / B]_HO_D94837_1E11 1 [MICA / B]_L0, (ii) SEQ ID NOs: XXX-XXXfor vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1 [MICAZB]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94837 1E11 1 [MICA / B]_H1_D94837_1E11_1 [MICA / B]_L2, (iv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 1E11 1[MICA / B]_H2_D94837_1E11 1 [MICA / B]_L2, (vi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of 2E5 [MICA / B]_H0_2E5 [MICA / B]_L0, (vii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L1, (viii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 2E5 [MICA / B]_H2_2E5 [MICA / B]_L2, (xi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B]_L0, (xii) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L1, (xiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B]_L2, (xiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L2, (xix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2F7[MICA / B]_H2_D99136_2F7 [MICA / B]_L2, (xxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O3388_1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L2, (xxiv) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D1O3388_1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L1, (xxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H0_D103388_lD7 [MICA / B]_L0, (xxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L1, (xxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B]_L1, (xxx) SEQ ID NOs: XXX-XXX for vhCDR 1-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICAZB]_L2, (xxxi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317_1A2 [MICA / B]_H0_D105317_1A2 [MICA / B]_L0, (xxxii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MIC A / B]_H1_D 105317 1 A2 [MICA / B]_L1, (xxxiii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JA2 [MICA / B]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D105317 1A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1 A2 [MICA / B]_H2_D 105317 1 A2 [MICA / B]_L2, (xxxvi) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D99136 2C11 [MICA / B]_HO_D99136_2C11 [MICA / B]_L0, (xxxvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L1, (xxxviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H1_D99136_2C11 [MICA / B]_L2, (xxxix) SEQ ID NOs: XXX-XXX for vhCDR 1-3and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2C11 [MICA / B]_H2_D99136_2C11 [MICA / B]_L2, (xli) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D103388 1B11-2 [MICA / B] HO DI 03388 IB 11 -2 [MICA / B] _L0, (xlii) SEQ ID NOs: XXX-XXX for vhCDRl - 3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 of DI 05317 1 C8 [MICA / B]_HO_D1O5317 1C8 [MICA / B ]_L0, (xliv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D1O5317 1F6 [MICA / B]_H0_D105317_lF6 [MICA / B ]_L0, (xlv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 of D105317JF7 [MICA / B]_H0_D105317_lF7 [MICA / B]_L0, (xlvi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837JD8 [MICA / B]_HO_D94837_1D8 [MICA / B]_L0, (xlviii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDR 1-3 ofD94837 1D9 [MICA / B ]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX forvlCDRl-3 ofD94837 1El [MICA / B]_HO_D94837_1E1 [MICA / B ]_L0, (1) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94852 2G8 [MICA / B]_H0_D94852_2G8 [MICA / B]_L0, (lii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 ofD88487_2A8 [MICA / B ]_H0_D88487_2A8 [MICA / B]_L0, (liii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D94837 3B12 [MICA / B]_H0_D94837_3B12 [MICA / B ]_L0, (liv) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99122 1H7 [MICA / B ]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D99136 2E8 [MICA / B]_H0_D99136_2E8 [MICA / B ]_L0, (Ivi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 6E1[MICA / B]_HO_6E1[MICA / B]_LO, (lix) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID NOs: XXX-XXX for vhCDRl-3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 13A9[MICA / B] HO 13 A9 [MICA / B] LO, and (Ixi) SEQ ID NOs: XXX-XXX for vhCDRl -3 and SEQ ID NOs: XXX-XXX for vlCDRl-3 of 1D5 [MICA / B]_HO_1D5 [MICA / B ]_L0, as depicted in Figures 21 and 22.

168. The heterodimeric antibody according to any one of claims 164-167, wherein the anti- MICA / B scFv comprises a variable heavy domain and variable light domain pair selected from the group consisting of: (i) SEQ ID Nos: XXX and XXX for D94837JE11_1 [MICA / B]_HO_D94837_1E11_1 [MICA / B ]_L0, (ii) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B ]_H1_D94837_1E11 1 [MICA / B]_L1, (iii) SEQ ID Nos: XXX and XXX for D94837 1E11_1 [MICA / B]_H1_D94837_1E11 1 [MICA / B]_L2, (iv) SEQ ID Nos: XXX and XXX for D94837_1E11_1 [MICA / B]_H2_D94837_1E11 1 [MICA / B]_L1, (v) SEQ ID Nos: XXX and XXX for D94837 1E11 1 [MICA / B] H2 D94837 1E11 1 [MICA / B] L2, (vi) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H0_2E5 [MICA / B ]_L0, (vii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H1_2E5 [MICA / B ]_L1, (viii) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B ]_H1_2E5 [MICA / B]_L2, (ix) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B]_L1, (x) SEQ ID Nos: XXX and XXX for 2E5 [MICA / B]_H2_2E5 [MICA / B ]_L2, (xi) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H0_D94852_2E12 [MICA / B ]_L0, (xii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L1, (xiii) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H1_D94852_2E12 [MICA / B ]_L2, (xiv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B]_H2_D94852_2E12 [MICA / B]_L1, (xv) SEQ ID Nos: XXX and XXX for D94852_2E12 [MICA / B ]_H2_D94852_2E12 [MICA / B]_L2, (xvi) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H0_D99136_2F7 [MICA / B]_L0, (xvii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B]_L1, (xviii) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H1_D99136_2F7 [MICA / B ]_L2, (xix) SEQ ID Nos: XXX and XXX for D99136_2F7 [MICA / B]_H2_D99136_2F7 [MICA / B]_L1, (xx) SEQ ID Nos: XXX and XXX for D99136 2F7[MICA / B] H2 D99136 2F7 [MICA / B]_L2, (xxi) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_HO_D1O3388_1C7 [MICA / B]_L0, (xxii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H1_D1O3388_1C7 [MICA / B]_L1, (xxiii) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B ]_H1_D1O3388_1C7 [MICA / B ]_L2, (xxiv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B] H2 D103388 1C7 [MICA / B] LI, (xxv) SEQ ID Nos: XXX and XXX for D103388 1C7 [MICA / B]_H2_D1O3388_1C7 [MICA / B]_L2, (xxvi) SEQ ID Nos: XXX and XXX for D1O3388_1D7 [MICA / B ]_HO_D1O3388_1D7 [MICA / B]_L0, (xxvii) SEQ ID Nos: XXX and XXX for D103388 1D7[MICA / B] H1 D103388 1D7 [MICA / B]_L1, (xxviii) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B ]_H1_D1O3388_1D7 [MICA / B]_L2, (xxix) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L1, (xxx) SEQ ID Nos: XXX and XXX for D103388 1D7 [MICA / B]_H2_D1O3388_1D7 [MICA / B ]_L2, (xxxi) SEQ ID Nos: XXX and XXX for D1O5317_1A2 [MICA / B ]_HO_D1O5317_1A2 [MICA / B]_L0, (xxxii) SEQ ID Nos: XXX and XXX for D105317_l A2 [MICA / B]_H1_D105317J A2 [MICA / B]_L1, (xxxiii) SEQ ID Nos: XXX and XXX for D105317_1A2 [MICA / B ]_H1_D1O5317_1A2 [MICA / B]_L2, (xxxiv) SEQ ID Nos: XXX and XXX for D105317_1 A2 [MICA / B]_H2_D1O5317_1A2 [MICA / B]_L1, (xxxv) SEQ ID Nos: XXX and XXX for D105317JA2 [MICA / B ]_H2_D1O5317_1A2 [MICA / B]_L2, (xxxvi) SEQ ID Nos: XXX and XXXfor D99136 2C11 [MICA / B ]_H0_D99136_2C 11 [MICA / B]_L0, (xxxvii) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H1_D99136_2C11 [MICA / B ]_L1, (xxxviii) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B ]_H1_D99136_2C 11 [MICA / B ]_L2, (xxxix) SEQ ID Nos: XXX and XXX for D99136 2C11 [MICA / B ]_H2_D99136_2C11 [MICA / B]_L1, (xl) SEQ ID Nos: XXX and XXX for D99136_2C11 [MICA / B]_H2_D99136_2C11 [MICA / B ]_L2, (xli) SEQ ID Nos: XXX and XXX for D103388 1B11-2 [MICA / B]_HO_D1O3388_1B11-2 [MICA / B ]_L0, (xlii) SEQ ID Nos: XXX and XXX for D105317 1B6 [MICA / B]_HO_D1O5317_1B6 [MICA / B]_L0, (xliii) SEQ ID Nos: XXX and XXX for D1O5317_1C8 [MICA / B]_HO_D1O5317_1C8 [MICA / B ]_L0, (xliv) SEQ ID Nos: XXX and XXX for D105317 1F6 [MICA / B ]_HO_D1O5317_1F6 [MICA / B ]_L0, (xlv) SEQ ID Nos: XXX and XXX for D1O5317_1F7 [MICA / B]_HO_D1O5317_1F7 [MICA / B]_L0, (xlvi) SEQ ID Nos: XXX and XXX for D94837 1D3 [MICA / B ]_HO_D94837_1D3 [MICA / B]_L0, (xlvii) SEQ ID Nos: XXX and XXX for D94837_1D8 [MICA / B ]_HO_D94837_1D8[MICA / B]_LO, (xlviii) SEQ ID Nos: XXX and XXX for D94837_1D9 [MICA / B]_HO_D94837_1D9 [MICA / B]_L0, (xlix) SEQ ID Nos: XXX and XXX for D94837 1E1 [MICA / B]_HO_D94837_1E1 [MICA / B]_L0, (1) SEQ ID Nos: XXX and XXX for D94852_2D4 [MICA / B]_H0_D94852_2D4 [MICA / B]_L0, (li) SEQ ID Nos: XXX and XXX for D94852 2G8 [MICA / B] HO D94852 2G8 [MICA / B] LO, (lii) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B ]_L0, (liii) SEQ ID Nos: XXX and XXX for D94837_3B12 [MICA / B ]_H0_D94837_3B12 [MICA / B]_L0, (liv) SEQ ID Nos: XXX and XXX for D99122 1H7 [MICA / B]_HO_D99122_1H7 [MICA / B]_L0, (Iv) SEQ ID Nos: XXX and XXX for D99136 2E8 [MICA / B ]_H0_D99136 2E8 [MICA / B]_L0, (Ivi) SEQ ID Nos: XXX and XXX for D88487_2A8 [MICA / B]_H0_D88487_2A8 [MICA / B]_L0, (Ivii) SEQ ID Nos: XXX and XXX for 3F9[MICA / B]_H0_3F9[MICA / B]_L0, (Iviii) SEQ ID Nos: XXX and XXX for 6E1[MICA / B]_HO_6E1 [MICA / B ]_L0, (lix) SEQ ID Nos: XXX and XXX for 7C6[MICA / B]_H0_7C6[MICA / B]_L0, (lx) SEQ ID Nos: XXX and XXX for 13A9 [MICA / B]_H0_13A9 [MICA / B]_L0, and (Ixi) SEQ ID Nos: XXX and XXX for 1D5 [MICA / B]_HO_1D5 [MICA / B]_L0, as depicted in Figures 21 and 22.

169. The heterodimeric antibody according to any one of claims 164-168, wherein the variable light domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

170. The heterodimeric antibody according to any one of claims 164-168, wherein the variable heavy domain of the anti-MICA / B scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker.

171. The heterodimeric antibody according to any one of claims 156-170, wherein the scFv linker is a charged scFv linker.

172. The heterodimeric antibody according to claim 171, wherein the scFv linker is a charged linker having the amino acid sequence (GKPGS)4 (SEQ ID NO: XXX).

173. The heterodimeric antibody according to any one of claims 156-172, wherein the first and second Fc domains are each variant Fc domains.

174. The heterodimeric antibody according to claim 173, wherein the first and / or second variantFc domains comprise one or more FcyRIIIA (CD16a) binding variant substitutions.

175. The heterodimeric antibody according to claim 174, wherein the one or more FcyRIIIA (CD16a) binding variant substitutions are selected from the group consisting of: (i) 236A, (ii) 239D, (iii) 239E, (iv) 243L, (v) 298A, (vi) 299T, (vii) 332E, (viii) 332D, (ix) 239D / 332E, (x) 236A / 332E, (xi) 239D / 332E / 330L, and (xii) 332E / 330L, wherein numbering is according to EU numbering.

176. The heterodimeric antibody according to claim 174 or 175, wherein the first and second variant Fc domains comprise a set of FcyRIIIA (CD16a) binding variant substitutions selected from the group consisting of: (i) S239D / I332E : S239D / I332E, (ii) S239D : S239D, (iii) I332E : I332E, (iv) WT : S239D / I332E, (v) WT : S239D, (vi) WT : I332E, (vii) S239D / I332E : WT, (viii) S239D : WT, (ix) I332E : WT, (x) S239D / I332E : S239D, (xi) S239D / I332E : I332E, (xii) S239D : S239D / I332E, (xiii) I332E : S239D / I332E, (xiv) S239D : I332E, and (xv) I332E : S239D, wherein numbering is according to EU numbering.

177. The heterodimeric antibody according to any one of claims 174-176, wherein the first and / or second variant Fc domains comprise the FcyRIIIA (CD 16a) binding variant substitutions of S239D / I332E, wherein numbering is according to EU numbering.

178. The heterodimeric antibody according to any one of claims 173-177, wherein the first and second variant Fc domains comprise a set of heterodimerization variants selected from the group consisting of those depicted in Figures 4A-4F, wherein numbering is according to EU numbering.

179. The heterodimeric antibody according to claim 178, wherein the set of heterodimerization variants is selected from the group consisting of: (i) S364K / E357Q : L368D / K370S, (ii) S364K : L368D / K370S, (iii) S364K : L368E / K370S, (iv) D401K : T411E / K360E / Q362E, and (v) T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering.

180. The heterodimeric antibody according to any one of claims 173-179, wherein the first and second variant Fc domains further comprise one or more ablation variants.

181. The heterodimeric antibody according to claim 180, wherein the one or more ablationvariants are E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

182. The heterodimeric antibody according to any one of claims 156-181, wherein one of the first or second variant Fc domain comprises one or more pl variants.

183. The heterodimeric antibody according to claim 182, wherein the one or more pl variants are N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

184. The heterodimeric antibody according to any one of claims 156-183, wherein the first monomer comprises amino acid variants S364K / E357Q / E233P / L234V / L235A / G236del / S267K, wherein the second monomer comprises amino acid variantsL368D / K370S / N208D / Q295E / N384D / Q418E / N421D / E233P / L234V / L235 A / G236del / S267K, and wherein numbering is according to EU numbering.

185. The heterodimeric antibody according to any one of claims 156-184, wherein the first and second monomers each further comprise amino acid variants M428L / N434S, M428L / 434A, or M252Y / S254T / T256E, wherein numbering is according to EU numbering.

186. A nucleic acid composition comprising nucleic acids encoding the first and second monomers and the light chain of the antibody according to any one of claims 156-185.

187. An expression vector comprising the nucleic acids according to claim 186.

188. A host cell transformed with an expression vector according to claim 187.

189. A method of making a heterodimeric antibody comprising:(a) culturing the host cell according to claim 188 under conditions wherein the heterodimeric antibody is expressed; and(b) recovering the heterodimeric antibody.

Citation Information

Patent Citations

  • Bispecific antibodies specific for PD1 and TIM3

    US10287352B2

  • Stable heterodimeric antibody design with mutations in the Fc domain

    US10457742B2

  • Stable heterodimeric antibody design with mutations in the Fc domain

    US10875931B2

  • Anti-CD28 compositions

    US11919958B2

  • Multimeric binding complexes

    US20040009149A1

Cited By

  • Anti-MICA / B antibody and application thereof

    CN120865416A

  • Anti-MICA / B antibody and application thereof

    CN120865417A